Document:

EX-10.4

 Exhibit 10.4 

***Text Omitted and Filed Separately with the Securities and Exchange Commission Confidential Treatment Requested Under 17 C.F.R. Sections
200.80(b)(4) and 230.406 
 COMMERCIAL LICENSE AGREEMENT 

This COMMERCIAL LICENSE AGREEMENT (this “Agreement”) is made this
21st day of August, 2013 (the “Effective Date”) between: 
 CYDEX
PHARMACEUTICALS, INC., a Delaware corporation with offices at 11119 North Torrey Pines Road, Suite 200, La Jolla, California 92037 (“CyDex”); and 

SAGE THERAPEUTICS INC., a Delaware corporation with offices at 29 Newbury Street, Suite 301, Boston,
Massachusetts 02116 (“Sage”). 
 RECITALS 

WHEREAS, CyDex is engaged in the business of developing and commercializing novel drug delivery technologies designed to enhance the
solubility and effectiveness of existing and development-stage drugs; 
 WHEREAS, CyDex is the exclusive supplier of Captisol®, a patented drug formulation system designed to enhance the solubility and stability of drugs; 

WHEREAS, Sage has developed or obtained certain rights related to the Compound (defined below); 

WHEREAS, Sage desires to obtain a license to use Captisol together with the Compound for the development and commercialization of the
Licensed Product (defined below) and the conduct of the Probe Studies and CyDex is willing to grant such license to Sage under the terms and conditions set forth herein; 

WHEREAS, CyDex and Sage entered into a Commercial License Agreement with an effective Date of December 13, 2012 (the “Old
Agreement” and such effective date, the “Old Agreement Effective Date”), which the parties are terminating as of the Effective Date; AND 

WHEREAS, on or about December 13, 2012, CyDex and Sage entered into a Supply Agreement, specifying the terms under which CyDex
would sell Captisol to Sage or its Contract Manufacturers (defined below), and Sage would obtain supplies of Captisol from CyDex, for use in development of and in the Licensed Product (the “Supply Agreement”). 

NOW, THEREFORE, in consideration of the following mutual promises and other good and valuable consideration, the receipt and
sufficiency of which are acknowledged, the parties, intending to be legally bound, agree as follows: 

 ***Text Omitted and Filed Separately with the Securities and Exchange Commission
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 
  

 1. DEFINITIONS. 

For the purposes of this Agreement, the following terms whether used in singular or plural form shall have the meanings as defined below: 

“Affiliate” means, with respect to any party, any entity controlling, controlled by, or under common control with such
party, during and for such time as such control exists. For these purposes, “control” shall refer to the ownership, directly or indirectly, of at least 50% of the voting securities or other ownership interest of the relevant entity.

 “Bankruptcy Code” means title 11 of the United States Code. 

“Captisol” means Captisol, also known scientifically as sulfobutylether
b(beta) cyclodextrin, sodium salt, and any modified or improved form of Captisol®, including without limitation, any improved or modified form of
sulfobutylether b(beta) cyclodextrin that is marketed with the use of the Captisol® trademark or a variation thereof. 

“Captisol Data Package” means (a) all toxicology/safety and other relevant scientific data owned, licensed or
developed by CyDex and its Affiliates relating to Captisol; and (b) all toxicology/safety and other relevant scientific data owned, licensed or developed by the licensees or sublicensees of CyDex or its Affiliates or other third parties (to the
extent permitted in the applicable license or other agreements between CyDex and/or its Affiliates and such licensees, sublicensees or other third parties), in each case relating to Captisol alone (and not in conjunction with a product
formulation). 
 “Captisol Improvement” means any modification or improvement of Captisol alone, whether or
not patentable, that is developed by Sage or its Affiliates, solely or jointly with a third party. For clarity, Captisol Improvements shall not include technology or improvements which are related to the Compound and/or other non-Captisol components
of the Licensed Product. 
 “Captisol Patents” means all patents and patent applications in the Territory which
pertain to Captisol, other than the Licensed Product Patents, and which now or at any time during the Term are owned by or licensed to CyDex or any CyDex Affiliate with the right to sublicense, including any and all extensions, renewals,
continuations, substitutions, continuations-in-part, divisions, patents-of-addition, reissues, reexaminations and/or supplementary protection certificates to any such patents. For avoidance of doubt, all intellectual property pertaining to the
Licensed Product or the Probe Study Product generated by Sage or its Affiliates or their Sublicensees during the Term of this Agreement or during the term of the Old Agreement shall be solely owned by Sage and shall not be part of the Captisol
Patents. The Captisol Patents include the patents and patent applications set forth on Exhibit A attached hereto. Such Exhibit A may be updated by CyDex from time to time during the Term. 

“Claim” has the meaning specified in Section 1.0.1. 

“Clinical Grade Captisol” means Captisol which (a) has been manufactured under conditions of current good
manufacturing practices for bulk excipients as set forth in U.S. Pharmacopoeia <1078> as of the Effective Date or any successor thereto, (b) is intended for use in humans, and (c) is intended for clinical trials for the Product.

 “Commercial Grade Captisol” means Captisol which (a) has been manufactured under conditions of current
good manufacturing practices for bulk excipients as set forth in U.S. Pharmacopoeia <1078> as of the Effective Date or any successor thereto, (b) is intended for use in humans, and (c) is intended for commercial sale of the
Product. 

  
 2 

 ***Text Omitted and Filed Separately with the Securities and Exchange Commission
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 
  

 “Commercial Launch Date” means the first commercial sale by Sage, its
Affiliates or Sublicensees of the Licensed Product to a Third Party. For avoidance of doubt, any transfer of the Licensed Product to a Third Party for preclinical, clinical or regulatory purposes shall not be deemed as commercial launch. 

“Commercially Reasonable Efforts” means those efforts consistent with the exercise of prudent scientific and business
judgment as applied by a party to the development and commercialization of its own pharmaceutical products at a similar stage of development and with similar market potential. 

“Compound” means that certain neuroactive steroid known as Allopregnanolone. 

“Confidential Information” has the meaning specified in Section 8.1. 

“Contract Manufacturer” has the meaning specified in Section 2.4. 

“Cover” (including variations thereof such as “Covered,” “Coverage,” or
“Covering”) means that the manufacture, use, importation or sale of the applicable Licensed Product or Probe Study Product would infringe a Valid Claim of a specified patent in the absence of a grant of rights under such patent. The
determination of whether an item or process is Covered by a Valid Claim shall be made on a country-by-country basis. 
 “Disclosing
Party” has the meaning specified in Section 8.1 hereof. 
 “DMF” means a Drug Master File for
Captisol, as filed as of the Effective Date, or as hereafter updated from time to time during the Term, by CyDex with the FDA. 

“FDA” means the United States Food and Drug Administration, or any successor thereto. 

“Field” means as applicable, either or both of the Epilepticus Field and the TBI Field, where the “Epilepticus
Field” means the field of therapeutic use against status epilepticus in humans and “TBI Field” means the treatment of traumatic brain injury in humans. 

“Indemnified Party” has the meaning specified in Section 10.4. 

“Indemnifying Party” has the meaning specified in Section 10.4. 

“License Agreement” means the License Agreement dated October 13, 2011 between CyDex and Sage. 

“Licensed Patents” means, collectively, the Captisol Patents and the Licensed Product Patents. 

“Licensed Product” means a pharmaceutical composition in and for the Field comprising the Compound combined with or
formulated using Captisol that is Covered by the Licensed Patents or that is developed with the assistance of or incorporates any component of the Captisol Data Package. For clarity, the Licensed Product shall not include any product the composition
of which includes the Compound and any other active pharmaceutical ingredient. 

  
 3 

 ***Text Omitted and Filed Separately with the Securities and Exchange Commission
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 
  

 “Licensed Product Patents” means all patents and patent applications
in the Territory which Cover the use of Captisol with the Compound, other than the Captisol Patents, and which now or at any time during the Term are owned by or licensed to CyDex or any CyDex Affiliate with the right to sublicense, including any
and all extensions, renewals, continuations, substitutions, continuations-in-part, divisions, patents-of-addition, reissues, reexaminations and/or supplementary protection certificates to any such patents. Licensed Product Patents further include
all other patents and patent applications, other than the Captisol Patents, which are owned or licensed by CyDex on the Effective Date or at any time during the Term of this Agreement, and which are necessary to develop, manufacture, and
commercialize the Licensed Product, or which arc necessary to develop or manufacture the Probe Study Product or which are necessary for Sage to exercise its license under this Agreement. Set forth in Exhibit B attached hereto is a list
of the Licensed Products Patents as of the Effective Date. Such Exhibit B may be updated by CyDex from time to time during the Term. 

“Losses” has the meaning set forth in Section 10.1. 

“Marketing Approval” means final approval of an NDA by the FDA for the United States, or final approval of a
comparable document filed with an equivalent health regulatory authority in any other country or in the European Union (using the centralized process or mutual recognition). 

“NDA” means a New Drug Application, as defined in the United States Federal Food, Drug and Cosmetic Act and the
regulations promulgated thereunder, or similar application filed with an equivalent regulatory body in another country. 

“Net Sales” means, with respect to a particular time period, the total gross amounts invoiced by Sage and its
Affiliates and their Sublicensees for sales of the Licensed Product made during such time period to unaffiliated Third Parties, less the following deductions to the extent actually allowed or incurred with respect to such sales: 

(a) reasonable and customary discounts (other than discounts which have already diminished the gross amount invoiced), including cash, trade
and quantity discounts, fees for service, patient assistance discounts, administrative fees, and rebates granted to trade customers, government, and distributors; provided that such discounts shall be subject to audit pursuant to
Section 5.3 below; 
 (b) credits or allowances granted for damaged, outdated, spoiled, returned or rejected products,
including, without limitation, in connection with recalls; 
 (c) freight, postage, insurance and transportation charges (if separately
identified on the invoice); and 
 (d) sales, use, value-added or excise taxes, tariffs, customs fees, duties or other governmental charges
(other than income taxes) levied on, absorbed or otherwise imposed on sales of the Licensed Product (if separately identified on the invoice), as adjusted by any refunds. 

Notwithstanding the foregoing, amounts invoiced by Sage and its Affiliates for the sale of the Licensed Product among Sage or its Affiliates for resale shall
not he included in the computation of Net Sales. For purposes of determining Net Sales, a “sale” shall not include reasonable transfers or dispositions as samples for promotional purposes, or transfers or dispositions at no cost for
preclinical, clinical or regulatory purposes. 

  
 4 

 ***Text Omitted and Filed Separately with the Securities and Exchange Commission
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 
  

 “Non-breaching Party” has the meaning specified in Section 13.2.

 “Notified Party” has the meaning specified in Section 13.2. 

“Pfizer” has the meaning specified in Section 8.5. 

“Pre-Existing Agreement” has the meaning ascribed to it in Sections 1.1 and 13 of the License Agreement. 

“Probe Condition” mean any of the following: (a) [...***...], (b) [...***...],
(c) [...***...], (d) [...***...], (e) [...***...], or (f) [...***...]. 
 “Probe
Study” means [...***...]. 
 “Probe Study Product” means [...***...]. 

“Receiving Party” has the meaning specified in Section 8.1. 

“Regulatory Approval” means, with respect to the Licensed Product in any country or jurisdiction, all approvals (including,
where required, pricing and reimbursement approvals and the applicable Marketing Approval), registrations, licenses or authorizations from the relevant regulatory authority in a country or jurisdiction that is specific to the Licensed Product and
necessary to market and sell such Licensed Product in such country or jurisdiction. 
 “Sage Know-How” means information or
data owned, licensed or generated by Sage and its Affiliates, before and during the Term of this Agreement or the term of the Old Agreement. For clarity, Sage Know-How shall not include information within the Captisol Data Package; nor does Sage
Know-How include any other information or data to which CyDex has obtained rights before the term of the Old Agreement, to the extent of such rights. 

“Sage Patents” means all patents and patent applications owned now, licensed or developed during the Term of this Agreement
or the term of the Old Agreement by Sage and its Affiliates, including any and all extensions, renewals, continuations, substitutions, continuations-in-part, divisions, patents-of-addition, reissues, reexaminations and/or supplementary protection
certificates to any such patents. For clarity, Sage Patents shall not include Licensed Patents under this Agreement. 

“Specifications” means the specifications for Captisol set forth in Exhibit C hereto, as such may be amended from
time to time. 
 “Study” has the meaning specified in Section 6.3. 

“Sublicensees” has the meaning specified in Section 2.3. 

  
 5 

 ***Text Omitted and Filed Separately with the Securities and Exchange Commission
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 
  

 “Term” has the meaning specified in Section 13.1. 

“Territory” means the entire world. 

“Third Party” means any person or entity or authority other than CyDex or Sage or an Affiliate of either of them. 

“Valid Claim” means a claim in any unexpired, issued patent which has not been irrevocably abandoned or held to be invalid or
unenforceable by a non-appealed or unappealable decision of a court or other authority of competent jurisdiction, which is not admitted to be invalid through disclaimer or dedication to the public, and which Covers the applicable Licensed Product or
Probe Study Product. 
 2. GRANT OF RIGHTS. 

2.1 License Grants from CyDex to Sage. 

(a) Field Licenses. 

(i) Licensed Patents. Subject to the terms and conditions of this Agreement, CyDex hereby grants to Sage an exclusive, nontransferable
(except as provided in Section 14.14) license during the Term under the Licensed Patents, solely to research, develop, make, have made, import, use, offer for sale and sell the Licensed Product in the Territory in and for the Field.
Notwithstanding the foregoing, to the extent that any Licensed Patents are licensed to CyDex or its Affiliates by a Third Party on a non-exclusive basis, the license granted to Sage in the foregoing sentence shall be exclusive as to CyDex but
non-exclusive as to such Third Party and other persons whose rights derive from such Third Party. Sage may not sublicense the Licensed Patents, except as expressly set forth in Section 2.3 and Section 2.4 below. 

(ii) Know-How License. Subject to the terms and conditions of this Agreement, CyDex hereby grants to Sage an exclusive,
nontransferable (except with respect to the assignment provision in Section 14.14) license during the Term under CyDex’s rights in and to the Captisol Data Package, solely to research, develop, make, have made, import, use, offer
for sale and sell the Licensed Product in the Territory in and for the Field. Notwithstanding the foregoing, to the extent that any contents of the Captisol Data Package are licensed to CyDex or its Affiliates by a Third Party on a non-exclusive
basis, the license granted to Sage in the foregoing sentence shall be exclusive as to CyDex but non-exclusive as to such Third Party and other persons whose rights derive from such Third Party. Sage may not sublicense its rights to the Captisol Data
Package, except as expressly set forth in Section 2.3 and Section 2.4 below. 
 (b) Probe Study Licenses.

 (i) Licensed Patents. Subject to the terms and conditions of this Agreement, CyDex hereby grants to Sage a non-exclusive,
nontransferable (except as provided in Section 14.14) license during the Term under the Licensed Patents, solely to research, develop, make, have made, import and use the Probe Study Product in the Territory in and for the Probe Studies.
Sage may not sublicense the Licensed Patents, except as expressly set forth in Section 2.3 and Section 2.4 below. 

  
 6 

 ***Text Omitted and Filed Separately with the Securities and Exchange Commission
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 
  

 (ii) Know-How License. Subject to the terms and conditions of this Agreement, CyDex
hereby grants to Sage a non-exclusive, nontransferable (except with respect to the assignment provision in Section 14.14) license during the Term under CyDex’s rights in and to the Captisol Data Package, solely to research, develop,
make, have made, import and use the Probe Study Product in the Territory in and for the Probe Studies. Sage may not sublicense its rights to the Captisol Data Package, except as expressly set forth in Section 2.3 and
Section 2.4 below. 
 (iii) Development and Commercialization License. Sage shall notify CyDex if Sage wishes subsequent
to a Probe Study to further develop a Probe Study Product for any Probe Condition for potential commercialization, in which event the parties shall negotiate in good faith a license agreement with commercially reasonable terms for a license of
appropriate scope. 
 (c) Scope of Licenses. CyDex grants no licenses or rights to use other than as expressly set forth herein.
Unless otherwise provided in this Agreement, CyDex grants no rights to Sage to manufacture, import, sell or offer for sale bulk Captisol. Sage acknowledges that not all rights of CyDex related to the manufacture of Captisol are included within the
rights licensed hereunder, given that CyDex shall supply Sage’s requirements of Captisol for the Licensed Product. Sage shall not attempt to reverse engineer, deconstruct or in any way determine the structure or composition of Captisol except
as and to the extent reasonably required to determine an optimal formulation of the Licensed Product or Probe Study Product, and such structure and composition (as and if so determined) shall be considered Confidential Information of CyDex. Sage
acknowledges and agrees that (i) CyDex shall not be required to obtain or maintain patent rights for the Licensed Patents, (ii) except as expressly provided herein, CyDex shall not be restricted in making sales of Captisol or licensing
rights to other parties, and (iii) CyDex does not warrant or indemnify Licensee or its Affiliates and Sublicensees against the Licensed Product infringing third party rights. 

(d) Non-Suit. During the term of this Agreement, neither CyDex nor any of its Affiliates shall sue or threaten to sue, or take any
similar action against, or aid, abet or enable any third party to sue, threaten to sue or take any similar action against. Sage, or any Sublicensees, or any of their respective Affiliates, or any customers or end-users of any Licensed Products, or
any users of any Probe Study Product, claiming that the manufacture, use, sale, offer for sale or importation of any Licensed Product, or the manufacture, use or importation of any Probe Study Product, infringes any patents or patent applications
owned, licensed, sublicensed or otherwise controlled by, now or in the future, CyDex or any of its Affiliates. 
 (e) Negative
Covenant. During the term of this Agreement, CyDex and its Affiliates shall not grant any rights to any Third Party that conflict with the exclusive rights granted herein to Sage or that conflict with or otherwise impair Sage’s ability to
conduct the activities described herein; provided, that, if CyDex negotiates toward and/or enters into a further agreement with a party to a Pre-Existing Agreement as expressly contemplated by such Pre-Existing Agreement (for example, upon
the exercise by such party of an option granted in a Pre-Existing Agreement), such negotiation and/or agreement shall not be deemed to impermissibly conflict with the exclusive rights granted herein to Sage or to impermissibly conflict with or
otherwise impair Sage’s ability to conduct the activities described herein and such further 

  
 7 

 ***Text Omitted and Filed Separately with the Securities and Exchange Commission
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 
  

 
agreement shall, from and after the date of execution and delivery, constitute a “Pre-Existing Agreement” for purposes of the definition of “Probe Condition” herein;
provided further that CyDex shall provide notice to Sage of the terms and conditions included in any such further agreement prior to executing same, Without limiting the generality of the foregoing, in the event that CyDex or any of its
Affiliates become aware that a Third Party is (other than as permitted by a Pre-Existing Agreement) conducting research, development or commercial activities using the Compound with Captisol, then CyDex shall take all reasonable measures to cease
the supply of Captisol to such Third Party and to any other Third Party that is determined to be supplying Captisol to such Third Party. Sage hereby acknowledges that CyDex’s performance of its obligations under any Pre-Existing Agreement, and
the exercise by a Third Party of its rights under any Pre-Existing Agreement, are hereby deemed not to be a breach by CyDex or any of its Affiliates of this Section 2.1(e). 

(f) Bankruptcy Code. All rights and licenses granted under or pursuant to this Agreement by CyDex to Sage are, and shall otherwise be
deemed to be, for purposes of Section 365(n) of the Bankruptcy Code, licenses of rights to “intellectual property” as defined under Section 101 of the Bankruptcy Code. The parties agree that Sage, as a licensee of such rights
under this Agreement, shall retain and may fully exercise all of its rights and elections under the Bankruptcy Code. 
 2.2 Grant of
License from Sage to CyDex. Sage hereby grants to CyDex a nonexclusive, transferable, perpetual, worldwide and royalty-free license, with the right to gran’ sublicenses (through multiple tiers of sublicensees), under Sage’s and its
Affiliates’ rights in and to Captisol Improvements to develop, make, have made, use, market, distribute, import, sell and offer for sale Captisol, any Captisol Improvement and products formulated with Captisol or any Captisol Improvement (in
each case, other than the Compound, the Licensed Product and any other compound that is a “Compound” under any other Commercial License Agreement entered into by and between Sage and CyDex and any other product that is a “Licensed
Product” under any other Commercial License Agreement entered into by and between Sage and CyDex). If during the Term any of (a) Sage, (b) Affiliates to whom Sage has provided rights under the licenses granted to Sage by CyDex
pursuant to Section 2.1, or (c) Sublicensees pursuant to the practice of their respective sublicenses from Sage under Section 2.3, tile any patent application claiming Captisol anywhere in the world, CyDex shall be
deemed automatically to have a nonexclusive, transferable, perpetual, worldwide and royalty-free license, with the right to grant sublicenses (through multiple tiers of sublicensees), under the claims relating specifically to Captisol to make, have
made, use, market, distribute, import, sell, and offer for sale Captisol and all products formulated with Captisol (in each case, other than the Compound, the Licensed Product and any other compound that is a “Compound” under any other
Commercial License Agreement entered into by and between Sage and CyDex and any other product that is a “Licensed Product” under any other Commercial License Agreement entered into by and between Sage and CyDex). Sage shall provide prompt
notice of any Captisol Improvement, and shall notify and consult with CyDex at least 30 days before the filing of any patent application claiming Captisol or any Captisol Improvement. Sage grants no licenses or rights to use other than as expressly
set forth herein. 

  
 8 

 ***Text Omitted and Filed Separately with the Securities and Exchange Commission
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 
  

 All rights and licenses granted under or pursuant to this Agreement by Sage to CyDex are, and shall otherwise
be deemed to be, for purposes of Section 365(n) of the Bankruptcy Code, licenses of rights to “intellectual property” as defined under Section 101 of the Bankruptcy Code. The parties agree that CyDex, as a licensee of such rights
under this Agreement, shall retain and may fully exercise all of its rights and elections under the Bankruptcy Code. 
 2.3
Sublicensing. Sage shall have the right to grant sublicenses to any Third Party (collectively “Sublicensees”) under the licenses granted to Sage pursuant to Section 2.1; provided that Sage warrants and
shall procure, as a condition precedent thereto, that each such Sublicensee shall first be advised of the restrictions set forth in this Agreement with respect to the transfer of the rights sublicensed to such Sublicensee and such Sublicensee shall
enter into an agreement (in a form reasonably satisfactory to CyDex, with CyDex named as an intended third-party beneficiary) with Sage pursuant to which such Sublicensee shall acknowledge and agree to observe and be bound by the applicable
restrictions set forth in this Agreement. Other than as specifically provided in this Section 2.3 and Section 2.4, Sage shall not have the right to grant sublicenses to any third party under the licenses granted pursuant to
Section 2.1. Sage shall ensure that all of its Sublicensees will comply with the terms and conditions of this Agreement and shall remain fully responsible for the compliance by such Sublicensees with the terms and conditions of this
Agreement as if such Sublicensees were Sage hereunder. 
 2.4 Contracting. Sage may manufacture the Licensed Product or the Probe
Study Product (but not the bulk Captisol) or contract the manufacture of the Licensed Product or the Probe Study Product (but not the manufacture of bulk Captisol) with reputable FDA-inspected third party manufacturers (each a “Contract
Manufacturer”) upon notification to CyDex in writing of Sage’s intent to do so (such notice to include the identity and location of the proposed Contract Manufacturers). To the extent necessary to engage a Contract Manufacturer tor the
Licensed Product or the Probe Study Product, Sage shall be permitted under this Agreement to grant any such Contract Manufacturer a sublicense under the licenses granted to Sage pursuant to Section 2.1 solely for such purposes; provided
that Sage warrants and shall procure, as a condition precedent thereto, that (a) any such Contract Manufacturer shall first be advised of the restrictions set forth in this Agreement with respect to the transfer of the rights licensed to Sage
mid its Sublicensees hereunder and (b) any such Contract Manufacturer shall enter into an agreement (in a form reasonably satisfactory to CyDex, with CyDex named as an intended third-party beneficiary) with Sage pursuant to which such Contract
Manufacturer shall acknowledge and agree to observe and be bound by the applicable restrictions set forth in this Agreement. Sage shall ensure that all of its Contract Manufacturers will comply with the terms and conditions of this Agreement and
shall remain fully responsible for the compliance by such Contract Manufacturers with the terms and conditions of this Agreement as if such Contract Manufacturers were Sage hereunder. 

2.5 Technology Transfer. CyDex shall, for a period of one year after the Old Agreement Effective Date, make its personnel available to
Sage and its Contract Manufacturers to respond to informational inquiries and provide technical assistance related to the Captisol Data Package. Sage shall compensate CyDex at the rate of $150 per hour for the time of CyDex personnel incurred to
provide such services. Such technology transfer shall not include information related to the manufacture of bulk Captisol. 

  
 9 

 ***Text Omitted and Filed Separately with the Securities and Exchange Commission
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 
  

 2.6 Negative Covenant by CyDex. During the Term of this Agreement, CyDex and its
Affiliates shall not develop or commercialize any pharmaceutical composition comprising the Compound in and for the Field, and shall not in any way assist any Third Party in developing or commercializing any pharmaceutical composition comprising the
Compound (including without limitation by granting any license or similar rights under intellectual property) in and for the Field. 
 3.
MANUFACTURE AND SUPPLY OF CAPTISOL. 
 The provisions of the Supply Agreement and any related quality agreement shall
govern the manufacture and supply of Captisol for use in the formulation of the Licensed Product or Probe Study Product, and nothing in the Supply Agreement (including Section 2.2 thereof) shall limit Sage’s right to use Probe Study
Product in accordance with the terms of this Agreement. 
 4. COMPENSATION. 

4.1 Payments and Royalties for Licenses. 

(a) One-Time Fees. 
 (i)
Upon the exercise of its option under the License Agreement to enter into the Old Agreement and the Supply Agreement, Sage has paid to CyDex a nonrefundable, one-time option exercise fee. Receipt of such fee is hereby acknowledged. 

(ii) In consideration of CyDex entering into this Agreement, Sage agrees to pay to CyDex $300,000 by wire transfer on the Effective Date. 

(b) Milestone Payments. Within ten (10) days following the occurrence of each of the milestone events listed below with respect to
the Licensed Product, Sage shall provide written notice to CyDex of the achievement of such milestone event, and within twenty (20) days of the occurrence of each of the milestone events, pay to CyDex the applicable nonrefundable milestone fee
listed next to each such event in further consideration of the rights granted Sage hereunder. The milestone payments (each payable only one time per Field regardless of the number of times achieved by the Licensed Product for the applicable Field;
for the avoidance of doubt, if the same Licensed Product achieves one or more given milestones for both the Epilepticus Field and the TBI Field, then the milestone payment for that event must be paid twice) are as follows. If any such milestone is
achieved before all prior sequential milestones have been actually achieved, then any and all prior sequential milestones which were not previously actually achieved shall be deemed to have thereby been achieved, and the milestone payments for such
deemed-achieved milestones shall also be payable within such twenty (20) days. 
  

					
	 	  	 MILESTONE
	  	MILESTONE
PAYMENT
	(i)	  	[...***...]	  	$[...***...]
	(ii)	  	[...***...]	  	$[...***...]
	(in)	  	[...***...]	  	$[...***...]
	(iv)	  	[...***...]	  	$[...***...]

  
 10 

 ***Text Omitted and Filed Separately with the Securities and Exchange Commission
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 
  

 (c) Royalties. In addition to amounts payable pursuant to Sections 4.1(a)
and 4.1(b) above, Sage shall make royalty payments to CyDex on a calendar quarterly basis, in amounts equal to [...***...]% times the Net Sales during such quarter arising from the sale of Licensed Products in the Territory in the Field
during the Term. All royalties payable to CyDex pursuant to this Section 4.1(c) shall be due and payable within 60 days after the conclusion of each calendar quarter. 

All royalties payable to CyDex pursuant to this Section 4.1(c) shall be due and payable within 60 days after the conclusion of
each calendar quarter. For avoidance of doubt, Net Sales under any other agreements entered into pursuant between the parties shall not be accumulated with Net Sales under this Commercial License Agreement for any purposes under this Agreement. 

Following the expiration of the last to expire Valid Claim within the Licensed Patents Covering the manufacture, use, sale or importation of a
Licensed Product in or into a given country of the Territory, Sage shall have the right to reduce by [...***...]% the royalty payments which would otherwise thereafter be owed pursuant to the first paragraph of this Section 4.1(c)
with respect to Net Sales arising from the sale of Licensed Product in such country. 
 For avoidance of doubt, the parties confirm
that if different royalty rates could apply to Net Sales of a particular unit of Licensed Product (e.g., manufactured in Country A but sold in Country B, and different royalty rates are then applicable to Country A than to
Country B), the higher of the royalty rates shall apply to such unit of Licensed Product. 
 In establishing the royalty
structure hereunder, the parties recognize, and Sage acknowledges, the substantial value of the various obligations being undertaken by CyDex under this Agreement, in addition to the grant of the licenses under the Captisol Data Package as well as
under the Licensed Patents, to enable the rapid and effective market introduction of the Licensed Product. The parties have agreed to the payment structure set forth herein as a convenient and fair mechanism to compensate CyDex for these
obligations. 
 (d) Probe Study Milestone Payment. Within ten (10) days following a new IND submission for a Probe Study or the
first submission of an amendment to an existing/open 1ND for a Probe Study, Sage shall provide written notice to CyDex of the achievement of such milestone event, and within twenty (20) days after the occurrence of such milestone event,
pay to CyDex $[...***...]. Such milestone payment shall be payable only one time; provided that it is not achieved more than five (5) times by a Probe Study Product; and provided that no more than five
(5) Probe Studies are performed. 
 4.2 Currency. All amounts due hereunder are stated in, and shall be paid in, U.S. dollars,
Net Sales based on foreign revenue will be converted to U.S. dollars at the rate of exchange published in The Wall Street Journal, Eastern U.S. Edition on the last day of each calendar quarter (or the last previous publication date if such
day is not a publication date). Sage shall provide CyDex, together with each royalty payment owed pursuant to Section 4.1(c) above, a schedule detailing the calculation of Net Sales resulting from the conversion of foreign revenue to
U.S. dollars as set forth herein. 

  
 11 

 ***Text Omitted and Filed Separately with the Securities and Exchange Commission
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 
  

 4.3 Taxes. All amounts due hereunder exclude all applicable sales, use, and other
taxes, and Sage will be responsible for payment of all such taxes (other than taxes based on CyDex’s income), fees, duties, and charges, and any related penalties and interest, arising from the payment of amounts due under this Agreement or the
sublicense or license, as the case may be, under the Licensed Patents and Captisol Data Package under this Agreement. The parties agree to cooperate with one another and use reasonable efforts to avoid or reduce tax withholding or similar
obligations in respect of royalties, milestone payments, and other payments made by Sage to CyDex under this Agreement. To the extent Sage is required to withhold taxes on any payment to CyDex, Sage shall pay the amounts of such taxes to the proper
governmental authority in a timely manner and promptly transmit to CyDex official receipts issued by the appropriate taxing authority and/or an official tax certificate, or such other evidence as CyDex may reasonably request, to establish that such
taxes have been paid. CyDex shall provide Sage any tax forms that may be reasonably necessary in order for Sage to not withhold tax or to withhold tax at a reduced rate under an applicable bilateral income tax treaty, CyDex shall use reasonable
efforts to provide any such tax forms to Sage at least 30 days before the due date for any payment for which CyDex desires that Sage apply a reduced withholding rate. Each party shall provide the other with reasonable assistance to enable the
recovery, as permitted by applicable law, of withholding taxes, value added taxes, or similar obligations resulting from payments made under this Agreement, such recovery to be for the benefit of the party bearing such withholding tax or value added
tax. 
 4.4 Late Payments. Payments that are not made when due hereunder shall accrue interest, from due date until paid, at a rate
equal to the prime rate, as reported in The Wall Street Journal, Eastern U.S. Edition, on the date such payment is due (or the last previous publication date if such day is not a publication date), plus an additional 200 basis points. 

5. RECORDS; REPORTS; AUDIT. 

5.1 Records. During the Term and for a period of three years thereafter, Sage shall, and shall require its Affiliates and Sublicensees
to, maintain accurate records relating to clinical study subject enrollment for Studies of the Licensed Product and Net Sales of the Licensed Product. 

5.2 Reports. 
 (a)
Quarterly Reports. Within 30 calendar days following the conclusion of each calendar quarter during the Term, Sage shall provide CyDex with written reports with respect to such calendar quarter (with a monthly breakdown) that describe in
reasonable detail Sage’s progress made toward achievement of the milestones specified in Section 4.1(h) above during such calendar quarter, including without limitation Sage’s then-current best estimate for the dates to achieve
such milestones and the number of human subjects enrolled during such calendar quarter in a clinical study conducted by or on behalf of Sage, its Affiliates and Sublicensees to support Marketing Approval for the Licensed Product and that received
Licensed Product during such calendar quarter. Within 60 calendar days following the conclusion of each calendar quarter during the Term, Sage shall provide CyDex with a written report with respect to such calendar quarter (with a monthly breakdown)
that sets forth in reasonable detail complete and accurate records of Sage’s, its Affiliates’ and Sublicensees’ Net Sales of the Licensed Product during such calendar quarter. 

  
 12 

 ***Text Omitted and Filed Separately with the Securities and Exchange Commission
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 
  

 (b) Annual Reports. Annually, by February 1st of each calendar year during the Term, Sage shall provide CyDex with written reports that: (i) update CyDex regarding development and commercial activities with respect to the Licensed Product,
(ii) describe in reasonable detail Sage’s progress made toward achievement of the milestones specified in Section 4.1(b) above during the preceding calendar year; (iii) summarize in reasonable detail Sage’s
communications and meetings involving the FDA related to Captisol as used in the Licensed Product during the preceding calendar year; (iv) detail Sage’s anticipated preclinical and clinical use of Captisol in the Licensed Product for the
then-current calendar year; (v) provide CyDex with Sage’s non-binding, reasonable, estimated rolling projection for sales of the Licensed Product, in terms of volume quantities and Net Sales values, for the then-current and the next two
succeeding calendar years; and (vi) set forth such other information regarding Captisol as mutually agreed upon by the parties. 
 5.3
Audit. Upon reasonable prior notice, such Section 5.1 records shall be available during regular business hours for examination and audit at the expense of CyDex, and not more often than once each calendar year, by an independent
certified public accountant selected by CyDex and reasonably acceptable to Sage, for the sole purpose of verifying the accuracy of the financial reports furnished by Sage pursuant to this Agreement. Any amounts shown to be owed but unpaid shall be
paid within 30 days from the accountant’s report from the original due date, plus interest accrued thereon (from the applicable original due date) at the rate set forth in Section 4.4 above. Any amounts shown to have been overpaid
shall be refunded within 30 days CyDex shall bear the full cost of such audit unless such audit discloses failure by Sage to pay any applicable milestone payment due or an underpayment by Sage of more than 5% of the amount due or any other material
inaccuracies in a Sage report, in which case Sage shall bear the full cost of such audit, plus (as in all eases of underpayment) the underpayment amount and interest at the rate set forth in Section 4.4 above. All information learned in
the course of any audit or inspection under this Section 5.3 shall be deemed to be Confidential Information of Sage, subject to the terms and provisions of Section 8 below, except to the extent necessary for CyDex to enforce
its rights under this Agreement. 
 6. DEVELOPMENT AND COMMERCIALIZATION BY SAGE. 

6.1 Diligence. Sage shall (i) use at least Commercially Reasonable Efforts, and shall further require its Affiliates and
Sublicensees to use at least Commercially Reasonable Efforts, to develop the Licensed Product, to seek Regulatory Approval of the Licensed Product in all countries and regions where it is commercially reasonable to so seek, and to commercialize the
Licensed Product in each respective country and region following Regulatory Approval of the Licensed Product in such respective country/region, and (ii) comply with the requirements set forth in Exhibit D hereto. If Sage is unable
to comply with the requirements set forth in Exhibit D hereto due to unanticipated events or changed circumstances that are beyond the reasonable control of Sage, including, for example, delays caused by changes to the development plan
that are required in the exercise of sound scientific or commercial judgment due to new information regarding the development of product candidates or changes to the applicable regulatory requirements, then the Parties shall meet and make reasonable
extensions to the 

  
 13 

 ***Text Omitted and Filed Separately with the Securities and Exchange Commission
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 
  

 
deadlines provided on Exhibit D. For clarity, Sage may meet the requirements of this Section 6.1 through its activities with respect to the Licensed Product in just one of
the Fields. In the event that Sage fails to meet the requirements of this Section 6.1, CyDex shall have the right to terminate this Agreement pursuant to Section 13.2 hereof 

6.2 Costs and Expenses. Other than those specified in this Agreement, Sage shall be solely responsible for all costs and expenses
related to its development and commercialization of the Licensed Product and its development of the Probe Study Product, including without limitation, all Sage’s costs and expenses associated with all preclinical activities and clinical trials,
and all regulatory filings and proceedings relating to the Licensed Product or the Probe Study Product. 
 6.3 In Vivo Studies. If
Sage wishes to conduct any in vivo study ([...***...], each a “Study”) [...***...], then Sage shall notify CyDex of any such Study and of the protocol therefor in writing at least [...***...] days before commencing such
Study, and the following provisions shall apply: 
 (a) Dosing. Sage shall not exceed the dosing matrix levels of Captisol indicated
by Exhibit E hereto without the written consent of CyDex. 
 (b) Review of Protocol. [...***...]. Sage shall give
due consideration and reasonably incorporate any input that CyDex provides regarding such protocol to the extent it pertains solely to the use and administration of Captisol. The contents of each such protocol shall be deemed to be Confidential
Information of Sage, subject to the terms and provisions of Section 8 below. 
 (c) Compliance with Laws. Sage represents
and warrants that each Study will be performed in accordance with all applicable laws, regulations and requirements. Sage will provide or cause to be provided all appropriate warnings to participants enrolled in each Study and obtain or cause to be
obtained appropriate documentation of informed consent from all participants in each such Study. 
 (d) Adverse Events. Sage agrees
to immediately inform CyDex if any adverse effects are observed and ascribed to Captisol in any Study in accordance with Section 7.3 hereof if applicable and in a reasonable and prompt manner if Section 7.3 hereof is not
applicable. To accurately track adverse events and preserve the validity of each Study, [...***...]. 
 (e) Reporting and Study
Data. Sage agrees to provide CyDex with copies of the final and full reports of all Studies conducted under this Section 6.3, promptly upon completion thereof, and Sage hereby grants to CyDex a non-exclusive, royalty-free license
(with the right to sublicense) to use and disclose such data as required by applicable law to [...***...]. 
 (f) Review of
Regulatory Filings and Publications. At least 14 days before a submission of any proposed written publication material or regulatory submission (which shall be subject to the restrictions of Section 8 hereof). Sage shall provide to
CyDex for CyDex’s review and comment a copy of any proposed written publication, material or regulatory submission reporting results of a Study where such publication material refers to [...***...]. Sage shall give due consideration and
reasonably incorporate any input that CyDex provides regarding [...***...]. 

  
 14 

 ***Text Omitted and Filed Separately with the Securities and Exchange Commission
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 
  

 6.4 Right of Reference. Sage shall have the right to reference the [...***...]
in connection with obtaining Regulatory Approval for the Licensed Product. 
 6.5 Access to Sage’s Data. [...***...], its
Sublicensees or Affiliates as required by applicable laws relating to adverse event reporting and/or in connection with development and commercialization of Captisol or for fulfilling its obligations under this Agreement, all at no cost to CyDex.
[...***...]. 
 7. REGULATORY MATTERS. 

7.1 Captisol Information Submitted for Regulatory Review. Except as otherwise set forth herein. Sage shall be solely responsible for all
communications with regulatory agencies in connection with the Licensed Product or with respect to Sage’s activities in connection with the Probe Study Product. Sage shall provide CyDex with copies of the portions of all regulatory submissions
containing Captisol data alone (and not in conjunction with any product formulation) 60 days before submission and shall allow CyDex to review and comment upon said submissions. The contents of each such submission shall be deemed to be Confidential
Information of Sage, subject to the terms and provisions of Section 8 below. Sage shall promptly inform CyDex of meetings with the FDA (or other regulatory agencies in the Territory) regarding the Licensed Product. If Sage submits
written responses to the FDA that include data on Captisol alone, CyDex shall be permitted to review such written materials before submission. If CyDex reasonably objects to the contents of such written responses relating to Captisol, the parties
agree to cooperate in working toward a reasonable and mutually agreeable response, provided that Sage shall be entitled to in good faith and with full regard for CyDex’s interests and concerns make the final determination as to the contents of
any such materials. 
 7.2 Material Safety. CyDex shall provide Sage, in writing, from time to time, with (a) relevant material
information currently known to it regarding handling precautions, toxicity and hazards with respect to Captisol, and (b) the then-current material safety data sheet for Captisol. CyDex warrants that all such information shall to CyDex’s
knowledge be complete and accurate. Notwithstanding the foregoing or anything in this Agreement to the contrary, with respect to any information that is provided in accordance with this Agreement by CyDex, Sage is solely responsible for (i) use
of such documentation, including without limitation, use in any regulatory submission to the FDA or any other regulatory agency, (ii) document control and retention, and (iii) determining the suitability of any such documentation for use
in any regulatory submission. 
 7.3 Adverse Event Reporting. Sage shall adhere, and shall require that its Affiliates, Sublicensees,
co-marketers and distributors adhere, to all requirements of applicable law and regulations that relate to the reporting and investigation of any adverse event, including without limitation an unfavorable and unintended diagnosis, symptom, sign
(including an abnormal laboratory finding), syndrome or disease, whether or not considered Captisol. Probe Study Product-related or Licensed Product-related, which occurs or worsens following administration of Captisol, Probe Study Product or
Licensed Product. Sage shall provide CyDex with copies of 

  
 15 

 ***Text Omitted and Filed Separately with the Securities and Exchange Commission
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 
  

 
all reports of any such adverse event which is serious (any such adverse event involving Captisol, the Probe Study Product or the Licensed Product that results in death, is life-threatening,
requires or prolongs inpatient hospitalization, results in disability, congenital anomaly or is medically important (i.e., may require other medical or surgical intervention to prevent other serious criteria from occurring)) which Sage
has reason to believe are associated with Captisol within 10 business days following (i) Sage’s submission of any such report to any regulatory agency, or (ii) receipt from Sage’s Sublicensee, co-marketer or distributor of any
such report to any regulatory agency. Sage shall also advise CyDex regarding any proposed labeling or registration dossier changes affecting Captisol. Reports from Sage shall be delivered to the attention of Chief Scientific Officer, CyDex, with a
copy to General Counsel, Ligand, at the address set forth in Section 14.7. The parties shall mutually cooperate with regard to investigation of any such serious adverse event, whether experienced by Sage, CyDex or any other Affiliate,
Sublicensee, co-marketer or distributor of CyDex or Sage. 
 7.4 Product Recalls. If any Captisol should be alleged or proven not to
meet the Specifications, Sage shall notify CyDex immediately, and both parties shall cooperate fully regarding the investigation and disposition of any such matter. In the event of a dispute arises between the parties as to whether or not Captisol
purchased by Sage meets the Specifications, such dispute shall be immediately resolved by submitting it to an independent quality control laboratory mutually agreed upon by the parties. The findings of such independent laboratory shall be binding
upon the parties. The cost of the independent quality control laboratory shall be borne by the party whose results are shown by such laboratory to have been incorrect. If (i) Sage and CyDex agree in writing that it is appropriate to recall any
Licensed Product, or (ii) the FDA requires the recall of any Licensed Product, and in either case, to the extent that such recall is due to issues relating to Captisol, then CyDex agrees, upon substantiation thereof, to bear a proportionate
share (based on the extent to which the recall was caused by issues relating to Captisol) of the reasonable direct costs associated with said recall, including a proportionate share of the actual cost of conducting the recall in accordance with the
recall guidelines of the applicable governmental authority, including without limitation, a proportionate share of the cost of the Licensed Product subject to the recall. Sage shall in all events be responsible for conducting any such recalls with
respect to the Licensed Product and shall maintain records of all sales of Licensed Product and customers sufficient to adequately administer any such recall, for a period of five years after termination of this Agreement. 

8. CONFIDENTIALITY. 
 8.1
Definition. Sage and CyDex each recognizes that, during the Term or the term of the Old Agreement, it may be (or was) necessary for a party (the “Disclosing Party”) to provide Confidential Information (as defined herein) to
the other party (the “Receiving Party”) that is highly valuable, the disclosure of which would be highly prejudicial to such party. The disclosure and use of Confidential Information will be governed by the provisions of this
Section 8. Neither Sage nor CyDex shall use the other’s Confidential Information except as expressly permitted in this Agreement. For purposes of this Agreement, “Confidential Information” means all information
disclosed by the Disclosing Party to the Receiving Party, whether under this Agreement or the Old Agreement, and which is obviously Confidential Information, or which is designated in writing by the Disclosing Party as “Confidential” (or
equivalent), or which when disclosed orally is declared to be confidential by the Disclosing Party 

  
 16 

 ***Text Omitted and Filed Separately with the Securities and Exchange Commission
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 
  

 
and confirmed in a writing delivered to the Receiving Party within 30 days of such disclosure, including but not limited to product specifications, data, know-how, formulations, product concepts,
sample materials, business and technical information, financial data, batch records, trade secrets, processes, techniques, algorithms, programs, designs, drawings, and any other information related to a party’s present or future products,
sales, suppliers, customers, employees, investors or business. Without limiting the generality of the foregoing, CyDex’s Confidential Information includes all materials provided as part of the Captisol Data Package, and Sage’s Confidential
Information includes Sage Patents and Sage Know-How. 
 8.2 Obligation. CyDex and Sage agree that they will disclose the other’s
Confidential Information to its (or its respective parent’s) own officers, employees, consultants and agents only if and to the extent necessary to carry out their respective responsibilities under this Agreement or in accordance with the
exercise of their rights under this Agreement, and such disclosure shall be limited to the maximum extent possible consistent with such responsibilities and rights. Neither party shall disclose Confidential Information of the other to any Third
Party without the other’s prior written consent, and any such disclosure to a Third Party shall be pursuant to the terms of a non-disclosure agreement no less restrictive than this Section 8. The party which disclosed Confidential
Information of the other to any Third Party shall be responsible and liable for any disclosure or use by such Third Party (or its discloses) which would have violated this Agreement if committed by the party itself. Neither party shall use
Confidential Information of the other except as expressly allowed by and for the purposes of this Agreement. Each party shall take such action to preserve the confidentiality of each other’s Confidential Information as it would customarily take
to preserve the confidentiality of its own Confidential Information {but in no event less than a reasonable standard of care). Unless otherwise specified in this Agreement and subject to terms and conditions in this Agreement, if so requested by the
other party a party shall promptly return all relevant records and materials in its possession or control containing or embodying the other party’s Confidential Information (including all copies and extracts of documents); provided,
however, that each party may retain one archival copy (and such electronic copies that exist as part of the party’s computer systems, network storage systems and electronic backup systems) of such records and materials solely to be able to
monitor its obligations that survive under this Agreement, 
 8.3 Exceptions. The use and non-disclosure obligations set forth in
this Section 8 shall not apply to any Confidential Information, or portion thereof, that the Receiving Party can demonstrate by appropriate documentation: 

(i) at the rime of disclosure is in the public domain; 

(ii) after disclosure, becomes part of the public domain, by publication or otherwise, through no fault of the Receiving Party or its
disclosees; 
 (iii) is independently developed by Receiving Party personnel with no reference or access to the Confidential Information;
or 
 (iv) is made available to the Receiving Party by an independent third party without obligation of confidentiality, provided, however,
that to the Receiving Party’s knowledge, such information was not obtained by said third party, directly or indirectly, from the Disclosing Party hereunder. 

  
 17 

 ***Text Omitted and Filed Separately with the Securities and Exchange Commission
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 
  

 In addition, the Receiving Party may disclose information that is required to be disclosed by
law, by a valid order of a court or by order or regulation of a governmental agency including but not limited to, regulations of the Securities and Exchange Commission, or in the course of litigation; provided that in all cases the Receiving
Party shall give the other party prompt notice of the pending disclosure and make a reasonable effort to obtain, or to assist the Disclosing Party in obtaining, a protective order or confidential-treatment order preventing or limiting (to the
greatest possible extent and for the longest possible period) the disclosure and/or requiring that the Confidential Information so disclosed be used only for the purposes for which the law or regulation required, or for which the order was issued.

 8.4 Injunction. Each party agrees that should it breach or threaten to breach any provisions of this Section 8, the
Disclosing Party will suffer irreparable damages and its remedy at law will be inadequate. Upon any breach or threatened breach by the Receiving Party of this Section 8, the Disclosing Party shall be entitled to seek temporary,
preliminary and/or permanent injunctive relief in addition to any other remedy which it may have, without need to post any bond or security, in addition to any and all other legal and equitable rights and remedies available to the Disclosing Party.

 8.5 Third Party Information. The parties acknowledge that the defined term “Confidential Information” shall include not
only a disclosing party’s own Confidential information but also Confidential Information of a Third Party which is in the possession of a disclosing party. 

Sage acknowledges that CyDex’s Confidential Information includes information developed by Pfizer that is confidential to both CyDex and
Pfizer. In so far as Confidential Information of Pfizer is disclosed, Pfizer is a third-party beneficiary of this Section 8 of this Agreement and may enforce it or seek remedies pursuant to it in accordance with its terms. 

Sage agrees not to disclose to CyDex any Confidential Information of a Third Party which is in the possession of Sage, unless CyDex has given
an express prior written consent (which specifies the owner of such Confidential Information) to receive such particular Confidential Information. If CyDex refuses to provide such consent, then any obligation of Sage to provide such information to
CyDex under this Agreement shall be deemed waived by CyDex. 
 8.6 Public Announcements. The parties will mutually agree on a press
release to be issued upon execution of this Agreement or reasonably soon thereafter. Neither party shall make any subsequent public announcement concerning this Agreement or the terms hereof not previously made public without the prior written
approval of the other party with regard to the form, content, and precise timing of such announcement, except as may be required to be made by either party in order to comply with applicable law, regulations, court orders, or tax, securities
filings, financing arrangements, acquisitions, or sublicenses. Such consent shall not be unreasonably withheld or delayed by such other party. Before any such public announcement, the party wishing to make the announcement will submit a draft of the
proposed announcement to the other party in sufficient time to enable such other party to consider and comment thereon. 

  
 18 

 ***Text Omitted and Filed Separately with the Securities and Exchange Commission
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 
  

 9. REPRESENTATIONS AND WARRANTIES. 

9.1 Mutual Representations and Warranties. Each party represents and warrants to the other (as of the Effective Date) as follows: 

(i) it is a corporation duly organized and validly existing under the laws of the state or country of its incorporation; 

(ii) it has the power and right to enter into this Agreement and to perform its obligations hereunder; 

(iii) this Agreement has been duly authorized, executed and delivered by such party and constitutes a legal, valid and binding obligation of
such party enforceable against such party in accordance with its terms except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, receivership, moratorium, fraudulent transfer, or other similar laws affecting the
rights and remedies of creditors generally and by general principles of equity; 
 (iv) the execution, delivery and performance of this
Agreement by such party do not conflict with any agreement, instrument or understanding, oral or written, to which such party is a party or by which such party may be bound, nor violate any law or regulation of any court, governmental body or
administrative or other agency having authority over such party; 
 (v) all consents, approvals and authorizations from all governmental
authorities or other third parties required to be obtained by such party in connection with the execution and delivery of this Agreement have been obtained: 

(vi) no person or entity has or will have, as a result of the transactions contemplated by this Agreement, any right, interest or valid claim
against or upon such party for any commission, fee or other compensation as a finder or broker because of any act by such party or its agents; and 

(vii) it has not entered into any agreement with any third party that is in conflict with the rights granted to the other party pursuant to
this Agreement. 
 9.2 CyDex Representation. CyDex owns all right, title and interest in and to, or in-licenses with the right to
sublicense, the Captisol Patents listed on Exhibit A attached hereto. 
 9.3 Disclaimer. THE WARRANTIES SET FORTH IN THIS
SECTION 9 AND IN THE SUPPLY AGREEMENT ARE PROVIDED IN LIEU OF, AND EACH PARTY HEREBY DISCLAIMS, ALL OTHER WARRANTIES, EXPRESS AND IMPLIED, RELATING TO THE SUBJECT MATTER OF THIS AGREEMENT, CAPTISOL, THE LICENSED PATENTS OR THE CAPTISOL
DATA PACKAGE, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE, TITLE AND NON-INFRINGEMENT OF THIRD PARTY RIGHTS. 

  
 19 

 ***Text Omitted and Filed Separately with the Securities and Exchange Commission
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 
  

 10. INDEMNIFICATION. 

10.1 By CyDex. CyDex shall defend, indemnify and hold Sage and its Affiliates and Sublicensees, and each of their respective directors,
officers, agents and employees, harmless from and against any and all losses, judgments, damages, liabilities, settlements, penalties, fines, costs and expenses (including the reasonable costs and expenses of attorneys and other professionals)
(collectively “Losses”) incurred by Sage as a result of any claim, demand, action or other proceeding (each, a “Claim”) by a Third Party, to the extent such Losses arise out of: (a) the manufacture, use,
handling, promotion, marketing, distribution, importation, sale or offering for sale of Captisol by CyDex and its Affiliates (including without limitation, the sale of Captisol by CyDex to Sage under the Supply Agreement); (b) infringement of
any person’s intellectual property rights in Captisol per se; (c) CyDex’s breach of this Agreement, including without limitation any of its representations and warranties set forth in Section 9.1, and
(d) CyDex’s negligence or misconduct. 
 10.2 By Sage. Sage shall defend, indemnify and hold CyDex and its Affiliates, and
each of their respective directors, officers, agents and employees, harmless from and against any and all Losses incurred by CyDex as a result of any Claim by a Third Party, to the extent such Losses arise out of: (a) the manufacture, use,
handling, promotion, marketing, distribution, importation, sale or offering for sale of the Licensed Product by Sage, its Affiliates and Sublicensees, or the manufacture, use, handling, distribution or importation of the Probe Study Product by Sage,
its Affiliates and Sublicensees; (b) any acts or omissions by Sage in connection with pre-clinical studies and clinical studies of actual or potential Licensed Products or Probe Study Products; (c) infringement of any person’s
intellectual property rights in connection with the subject matter of this Agreement (other than intellectual property rights in Captisol per se); (d) Sage’s breach of this Agreement, including without limitation any of its
representations and warranties set forth in Section 9.1 and (e) Sage’s negligence or misconduct. 
 10.3
Expenses. As the parties intend complete indemnification, all costs and expenses of enforcing any provision of this Section 10 shall also be reimbursed by the indemnifying Party. 

10.4 Procedure. 
 (a) The
person intending to claim indemnification under this Section 10 (an “Indemnified Party”) shall promptly notify the other party (the “Indemnifying Party”) of any Claim in respect of which the Indemnified
Party intends to claim such indemnification, and a reasonable explanation of the basis for the Claim and the amount of alleged Losses to the extent of the facts then known by the Indemnified Party. (Notwithstanding the foregoing, no delay or
deficiency on the part of the Indemnified Party in so notifying the Indemnifying Party will relieve the Indemnifying Party of any liability or obligation under this Agreement except to the extent the Indemnifying Party has suffered actual prejudice
directly caused by the delay or other deficiency.) The Indemnifying Party shall assume the defense thereof whether or not such Claim is rightfully brought; provided, however, that if the Indemnifying Party assumes the defense, the Indemnified
Party shall have the right to employ counsel separate from counsel employed by the Indemnifying Party in any such action and to participate in the defense thereof, but the fees and expenses of such counsel employed by the Indemnified Party shall be
at the sole cost and expense of the Indemnified Party unless the Indemnifying Party consents to the retention of such 

  
 20 

 ***Text Omitted and Filed Separately with the Securities and Exchange Commission
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 
  

 
counsel or unless the named parties to any action or proceeding include both the Indemnifying Party and the Indemnified Party and a representation of both the Indemnifying Party and the
Indemnified Party by the same counsel would be inappropriate due to the actual or potential differing interests between them. And provided further that, if the Indemnifying Party shall fail to assume the defense of and reasonably defend such
Claim, the Indemnified Party shall have the right to retain or assume control of such defense and the Indemnifying Party shall pay (as incurred and on demand) the fees and expenses of counsel retained by the Indemnified Party. 

(b) The Indemnifying Party shall not be liable for the indemnification of any Claim settled (or resolved by consent to the entry of judgment)
without the written consent of the Indemnifying Party. Also, if the Indemnifying Party shall control the defense of any such Claim, the Indemnifying Party shall have the right to settle such Claim; provided, that the Indemnifying Party shall
obtain the prior written consent (which shall not be unreasonably withheld or delayed) of the Indemnified Party before entering into any settlement of (or resolving by consent to the entry of judgment upon) such Claim unless (i) there is no
finding or admission of any violation of law or any violation of the lights of any Person by an Indemnified Party, no requirement that the Indemnified Party admit fault or culpability, and no adverse effect on any other claims that may be made by or
against the Indemnified Party and (ii) the sole relief provided is monetary damages that are paid in full by the Indemnifying Party and such settlement does not require the Indemnified Party to take (or refrain from taking) any action. 

(c) Regardless of who controls the defense, the other party hereto shall reasonably cooperate m the defense as may be requested. Without
limitation, the Indemnified Party, and its directors, officers, advisers, agents and employees, shall cooperate fully with the Indemnifying Party and its legal representatives in the investigations of any Claim. 

11. LIMITATION OF LIABILITY. 
 EXCEPT FOR
DAMAGES FOR WHICH A PARTY IS RESPONSIBLE PURSUANT TO ITS INDEMNIFICATION OBLIGATIONS SET FORTH IN SECTION 10 ABOVE, EACH PARTY SPECIFICALLY DISCLAIMS ALL LIABILITY FOR AND SHALL IN NO EVENT BE LIABLE FOR ANY INCIDENTAL, SPECIAL, INDIRECT
OR CONSEQUENTIAL DAMAGES, EXPENSES, LOST PROFITS, LOST SAVINGS, INTERRUPTIONS OF BUSINESS OR OTHER DAMAGES OF ANY KFND OR CHARACTER WHATSOEVER ARISING OUT OF OR RELATED TO THIS AGREEMENT OR RESULTING FROM THE MANUFACTURE, HANDLING, MARKETING, SALE,
DISTRIBUTION OR USE OF LICENSED PRODUCT OR USE (PURSUANT TO OR IN CONNECTION WITH THE RIGHTS GRANTED UNDER THIS AGREEMENT) OF THE LICENSED PATENTS AND CAPTISOL DATA PACKAGE, REGARDLESS OF THE FORM OF ACTION, WHETHER IN CONTRACT, TORT, STRICT
LIABILITY OR OTHERWISE, EVEN IF SUCH PARTY WAS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. EXCEPT WITH RESPECT TO THE INDEMNIFICATION SPECIFICALLY PROVIDED IN Section 10 ABOVE, IN NO EVENT SHALL EITHER PARTY’S TOTAL AGGREGATE LIABILITY FOR
ALL CLAIMS ARISING OUT OF OR RELATED TO THIS AGREEMENT OR RESULTING FROM THE MANUFACTURE, HANDLING, MARKETING, SALE, DISTRIBUTION OR USE OF LICENSED PRODUCT OR PROBE STUDY PRODUCT OR USE OF THE LICENSED PATENTS AND CAPTISOL DATA PACKAGE PURSUANT TO
OR IN CONNECTION 

  
 21 

 ***Text Omitted and Filed Separately with the Securities and Exchange Commission
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 
  

 
WITH THE RIGHTS GRANTED UNDER THIS AGREEMENT EXCEED THE GREATER OF (I) $250,000 AND (II) THE TOTAL AMOUNTS ACTUALLY PAID UNDER THIS AGREEMENT BY SAGE TO CYDEX AS OF THE DATE SUCH CLAIM
ARISES, PROVIDED, THAT THE FOREGOING LIMITATIONS SHALL NOT LIMIT CYDEX’S RIGHT TO TAKE ACTION TO ENFORCE THIS COMMERCIAL LICENSE AGREEMENT TO COLLECT AMOUNTS THAT ARE PROPERLY DUE AND OWING UNDER ARTICLE 4 HEREOF, NO ACTION,
REGARDLESS OF FORM, ARISING OUT OF OR RELATED TO THIS AGREEMENT MAY BE BROUGHT BY EITHER PARTY MORE THAN TWO YEARS AFTER SUCH PARTY HAS KNOWLEDGE OF THE LEGAL AND FACTUAL BASIS EOR SUCH CAUSE OF ACTION OR AFTER EXPIRATION OF THE APPLICABLE STATUTORY
LIMITATIONS PERIOD, WHICHEVER IS SOONER. FOR AVOIDANCE OF DOUBT, THE PARTIES’ RESPECTIVE RIGHTS AND OBLIGATIONS WITH RESPECT TO ANY LIABILITY THAT MAY ACCRUE UNDER THE LICENSE AGREEMENT, ANY COMMERCIAL LICENSE AGREEMENT (OTHER THAN THIS
AGREEMENT) OR ANY SUPPLY AGREEMENT OR IN CONNECTION WITH ACTIVITIES CONDUCTED PURSUANT TO OR CONTEMPI ATFD BY ANY SUCH AGREEMENTS SHALL BE DETERMINED PURSUANT TO THE TERMS OF THOSE AGREEMENTS AND NOT BY THE TERMS AND CONDITIONS SET FORTH IN THIS
AGREEMENT. 
 12. MANAGEMENT OF LICENSED PATENTS. 

12.1 Prosecution and Maintenance. 

(a) CyDex Patents. CyDex shall maintain, at its sole cost and expense and using reasonable discretion, the Captisol Patents. CyDex shall
have the sole right to control the prosecution and maintenance of patent applications and the selection of countries where patent applications arc tiled related to the Captisol Patents. CyDex agrees that, during the Term, it will use Commercially
Reasonable Efforts to prosecute, obtain and maintain the Captisol Patents in the United States, China, Japan and the European Union. In the event that CyDex decides not to prosecute and maintain the Captisol Patents in a country or countries which
is not a major market, CyDex shall provide not less than 30 days prior written notice of such decision, and Sage shall have the option to take over the prosecution and maintenance in such country or countries. 

(b) Licensed Product Patents. Sage shall have the right to maintain, at its sole cost and expense and using reasonable discretion, the
Licensed Product Patents. Sage shall have the sole right to control the prosecution and maintenance of patent applications and the selection of countries where patent applications are filed related to the Licensed Product Patents, provided that
CyDex shall be provided with the right and opportunity to give comments and recommendations as to the overall strategy regarding the filing, prosecution and maintenance of the Licensed Product Patents. In the event that Sage decides not to prosecute
and maintain the Licensed Product Patents in a country or countries, Sage shall provide not less than 30 days prior written notice of such decision, and CyDex shall have the option to take over the prosecution and maintenance in such country or
countries. 

  
 22 

 ***Text Omitted and Filed Separately with the Securities and Exchange Commission
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 
  

 (c) Sage Patents and Sage Know-How. Sage shall be the sole and exclusive owner of Sage
Patents and Sage Know-How. Sage, at its own cost and expense, shall be solely responsible for prosecuting and maintaining Sage Patents. 

12.2 Infringement of Captisol Patents by Third Parties. 

(a) If Sage becomes aware that a third party may be infringing a Captisol Patent, it will promptly notify CyDex in writing, providing all
information available to Sage regarding the potential infringement. CyDex shall take whatever, if any, action it deems appropriate, in its sole discretion, against the alleged infringer. If CyDex elects to take action, Sage shall, at CyDex’s
request and expense, cooperate and shall cause its employees and advisers to cooperate with CyDex in taking any such action, including but not limited to, cooperating with the prosecution of any infringement suit by CyDex related to a Captisol
Patent. Sage shall not take any such action against the alleged infringer related to a Captisol Patent without the written consent of CyDex. 

(b) If Sage becomes aware that a third party may be infringing a Licensed Product Patent, it will promptly notify CyDex in writing, providing
all information available to Sage regarding the potential infringement. Sage shall take whatever, if any, action it deems appropriate, in its sole discretion, against the alleged infringer if such infringement affects any of Sage’s rights with
respect to a Licensed Product. If Sage elects to take action, CyDex shall, at Sage’s request and expense, cooperate and shall cause its employees and advisers to cooperate with Sage in taking any such action, including but not limited to,
cooperating with the prosecution of any infringement suit by Sage related to a Licensed Product Patent. CyDex shall not take any such action against the alleged infringer related to a Licensed Product Patent without the written consent of Sage. 

13. TERM AND TERMINATION. 
 13.1
Term. The term of this Agreement (the “Term”) shall commence on the Effective Date and shall continue in effect unless and until terminated as set forth herein. Upon the expiration or termination of the Term, this Agreement,
and the rights, licenses and obligations granted hereunder, shall terminate, subject only to Section 13.5. 
 13.2
Termination for Breach. 
 (a) Notice. If either party believes that the other is in material breach of this Agreement,
then the party holding such belief (the “Non-breaching Party”) may deliver notice of such breach to the other party (the “Notified Party”). The Notified Party shall have [...***...] days to cure such breach to
the extent involving non-payment of amounts due hereunder, and [...***...] days to either cure such breach for all other material breaches, or, if cure of such breach other than non-payment cannot reasonably be effected within such
[...***...] day period, to deliver to the Non-breaching Party a plan reasonably calculated to cure such breach within a timeframe that is reasonably prompt in light of the circumstances then prevailing but in no event in excess of an
additional [...***...] day period. Following delivery of such a plan, the Notified Party shall diligently carry out the plan and cure the breach and the cues period shall be extended by the time period provided in such plan but in no event to
exceed [...***...] days from the date of any initial breach notice delivered under this Section 13.2. 

  
 23 

 ***Text Omitted and Filed Separately with the Securities and Exchange Commission
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 
  

 (b) Failure to Cure. If the Notified Party fails to cure a material breach of this
Agreement as provided for in Section 13.2, then the Non-breaching Party may terminate this Agreement upon written notice to the Notified Party. 

13.3 Sage Right to Terminate. Sage shall have the right to terminate this Agreement, without cause, on 180 days’ prior
written notice to CyDex. 
 13.4 Termination of the Supply Agreement. For clarity, this Agreement shall terminate if the
Supply Agreement is terminated. 
 13.5 Survival. Notwithstanding any other provisions of this Agreement, any liability or obligation of
either party to the other for acts or omissions before the termination of this Agreement shall survive the termination of this Agreement. And, such termination shall not relieve either party from obligations that are expressly indicated to survive
termination of this Agreement, nor shall any termination of this Agreement relieve Sage of its obligation to pay CyDex royalties for all Licensed Product sold by Sage, its Affiliates or Sublicensees before the effective date of such termination.
Sections 2.2 (Grant of License from Sage to CyDex), 4.1 (Payments and Royalties for Licenses) (to the extent owed but unpaid as of the date of termination of this Agreement), 4.2 (Currency),
4.3 (Taxes), 4.4 (Late Payments), 5 (Records; Reports; Audits), 6.5 (Access to Sage’s Data), 7.3 (Adverse Event Reporting), 7.4 (Product Recalls),
8 (Confidentiality), 9.3 (Disclaimer), 10 (Indemnification), 11 (Limitation of Liability), 13.5 (Survival), and 14 (General Provisions) shall survive termination of this
Agreement. 
 14. GENERAL PROVISIONS. 

14.1 Non-Solicitation. During the Evaluation Period (as defined in the License Agreement) and for a period of one year
thereafter, neither party shall solicit any employee of the other party to terminate his or her employment with such other party or to breach any other obligation to such other party. This section is not meant to encompass general solicitations such
as may be found in newspaper advertisements and the like. 
 14.2 Relationship of Parties. Each of the parties hereto
is an independent contractor and nothing in this Agreement is intended or shall be deemed to constitute a partnership, agency, employer-employee or joint venture relationship between the parties. No party shall have the right to, and each party
agrees not to purport to, incur any debts or make any commitments or contracts for the other, 
 14.3 Compliance with
Law. Each of the parties shall comply with all applicable international, federal, state and local laws, rules and regulations, including, but not limited to, import/export restrictions, laws, rules and regulations governing product quality and
safety and patent, copyright and trade secret protection. 

  
 24 

 ***Text Omitted and Filed Separately with the Securities and Exchange Commission
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 
  

 14.4 Arbitration. 

(a) Procedure. Except as otherwise expressly set forth in this Agreement, any and all disputes or controversies arising out of or
relating to this Agreement shall be exclusively and finally resolved by binding arbitration in accordance with the commercial arbitration rules of the American Arbitration Association then in effect, in Boston, Massachusetts. The arbitration shall
be conducted by an arbitrator reasonably knowledgeable about the pharmaceutical industry and acceptable to CyDex and Sage. If CyDex and Sage cannot agree on a single arbitrator within 30 days after a demand for arbitration has been made, CyDex shall
appoint an arbitrator, Sage shall appoint an arbitrator, the two arbitrators shall appoint a third arbitrator, and the three arbitrators shall hear and decide the issue in controversy. If either party fails to appoint an arbitrator within 45 days
after service of the demand for arbitration, then the arbitrator appointed by the other party shall arbitrate any controversy in accordance with this Section 14.4(a). Except as to the selection of arbitrators, the arbitration proceedings
shall be conducted promptly and in accordance with the rules of the American Arbitration Association then in effect. The expenses of any arbitration, including the reasonable attorney fees of the prevailing party, shall be borne by the party deemed
to be at fault or on a pro-rata basis should the arbitration conclude in a finding of mutual fault. 
 (b) Confidentiality of
Proceedings. All arbitration proceedings hereunder shall be confidential and the arbitrator(s) shall issue appropriate protective orders to safeguard each party’s Confidential Information. Except as required by law, no party shall make (or
instruct the arbitrator(s) to make) any public announcement with respect to the proceedings or decision of the arbitrators) without prior written consent of the other party. 

(c) Interim Equitable Relief. Notwithstanding Section 14.4(a), but subject to the limitations set forth in
Article 11, each party shall not be precluded from seeking equitable relief (including but not limited to interim injunctive relief) in any court having jurisdiction to protect its interests. 

(d) Binding Effect. The provisions of this Section 14.4 shall survive any termination of this Agreement, and shall be
severable and binding on the parties hereto, notwithstanding that any other provision of this Agreement may be held or declared to be invalid, illegal or unenforceable. 

14.5 Costs and Expenses. Except as otherwise expressly provided in this Agreement, each party shall bear all costs and expenses
associated with the performance of such party’s obligations under this Agreement. 
 14.6 Force Majeure. Neither
party shall be liable for failure to perform, or delay in the performance of, its obligations under this Agreement (other than payment obligations) when such failure or delay is caused by an event of force majeure. For purposes of this Agreement, an
event of force majeure means any event or circumstance beyond the reasonable control of the affected party, including but not limited to, war, insurrection, riot, fire, flood or other unusual weather condition, explosion, act of God, peril of the
sea, strike, lockout or other industrial disturbance, sabotage, accident, embargo, breakage of machinery or apparatus, injunction, act of governmental authority, compliance with governmental order or national defense requirements, 

  
 25 

 ***Text Omitted and Filed Separately with the Securities and Exchange Commission
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 
  

 
or inability to obtain fuel, power, raw materials, labor or transportation facilities. If, due to any event offeree majeure, either party shall be unable to fulfill its obligations under this
Agreement (other than payment obligations), the affected party shall immediately notify the other party of such inability and of the period during which such inability is expected to continue and the time for performance shall be extended for a
number of days equal to the duration of the force majeure. 
 14.7 Notices. Any notice, request, or communication under this
Agreement shall be effective only if it is in writing and personally delivered; sent by certified mail, postage pre-paid; facsimile with receipt confirmed; or by nationally recognized overnight courier with signature required, addressed to the
parties at the addresses stated below or such other persons and/or addresses as shall be furnished in writing by any party in accordance with this Section 14.7. Unless otherwise provided, all notices shall be sent: 

If to CyDex, to: 
 CyDex
Pharmaceuticals, Inc. 
 11119 North Torrey Pines Road, Suite 200 

La Jolla, CA 92037 
 Attention:
President 
 Fax: (858) 550-7272 

With a copy to: 
 General Counsel

 Ligand Pharmaceuticals Incorporated 

11085 North Torrey Pines Road, Suite 200 

La Jolla, CA 92037 
 Fax:
(858)550-7272 
 If to Sage, to: 

Sage Therapeutics, Inc. 
 29
Newbury Street, Suite 301 
 Boston, MA 02116 

Attention: President 
 Fax:
(617) 859-2891 
 If sent by facsimile transmission, the date of transmission shall be deemed to be the date on which such notice,
request or communication was given. If sent by overnight courier, the next business day after the date of deposit with such courier shall be deemed to be the date on which such notice, request or communication was given. If sent by certified mail,
the third business day after the date of mailing shall be deemed the date on which such notice, request or communication was given. 

  
 26 

 ***Text Omitted and Filed Separately with the Securities and Exchange Commission
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 
  

 14.8 Use of Name; Publicity. No party shall use the name, trademark, trade name or
logo of the other party, its Affiliates or their respective employee(s) in any publicity, promotion, news release or public disclosure relating to this Agreement or its subject matter, without the prior express written permission of the other party,
except as may be required by law or the rules of NASDAQ. The parties agree that a party may disclose this Agreement’s existence and terms, and material developments or material information generated under this Agreement, in (i) securities
filings with the Securities and Exchange Commission (or equivalent foreign agency) to the extent required by law, or (ii) under conditions of confidentiality/nonuse in connection with investment and similar corporate transactions.
Notwithstanding the above, once a public announcement has been made, either party shall be free to disclose to third parties any information contained in said public announcement. In the event of a required public announcement, the party making such
announcement shall provide the other party with a copy of the proposed text before such announcement sufficiently in advance of the scheduled release of such announcement to afford such other party a reasonable opportunity to review and comment upon
the proposed text and the timing of such disclosure. 
 14.9 Governing Law. This Agreement shall be governed by and construed
in accordance with the internal laws of the State of California (without giving effect to any conflicts of law principles that require the application of the law of a different state). 

14.10 Entire Agreement; Amendment. The Commercial License Agreement and all Exhibits attached hereto contain the entire
agreement of the parties relating to the subject matter hereof and thereof and supersede any and all prior or contemporaneous agreements, written or oral, between CyDex (and/or any of its Affiliates) and Sage (and/or any of its Affiliates) relating
to the subject matter hereof and thereof, including, without limitation, the Old Agreement; provided, that (a) any confidentiality/nonuse provisions of any prior agreement (other than the Old Agreement) are not superseded and will remain in
effect in addition to the confidentiality/nonuse provisions hereof, (b) the provisions stated to survive termination of the Old Agreement, as set forth in Section 13.5 therein, shall survive, other than Sections 6.3,
8 and 13.3, which are hereby terminated, and Section 4 therein shall survive only with respect to amounts owed but unpaid as of the Effective Date), and (c) the Supply Agreement is not superseded and will remain in
effect. This Agreement cannot be amended except by way of an express writing signed by both parties. 
 14.11 Binding
Effect. This Agreement shall be binding upon, and the rights and obligations hereof shall apply to, CyDex and Sage and any successor(s) and permitted assigns. The name of a party appearing herein shall be deemed to include the names of such
party’s successors and permitted assigns to the extent necessary to carry out the intent of this Agreement. 
 14.12
Waiver. The rights of either party under this Agreement may be exercised from time to time, singularly or in combination, and the exercise of one or more such rights shall not be deemed to be a waiver of any one or more of the others. No
waiver of any breach of a term, provision or condition of this Agreement shall be deemed to have been made by either party unless such waiver is addressed in writing and signed by an authorized representative of that party. The failure of either
party to insist upon the strict performance of any of the terms, provisions or conditions of this Agreement, or to exercise any option contained in this Agreement, shall not be construed as a waiver or relinquishment for the future of any such term,
provision, condition or option or the waiver or relinquishment of any other term, provision, condition or option. 

  
 27 

 ***Text Omitted and Filed Separately with the Securities and Exchange Commission
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 
  

 14.13 Severability. If any provision of this Agreement is determined by a final
and binding court or arbitration judgment to be invalid, illegal or unenforceable to any extent, such provision shall not be not affected or impaired up to the limits of such invalidity, illegality or unenforceability; the validity, legality and
enforceability of the remaining provisions of this Agreement shall not be affected or impaired in any way; and the parties agree to negotiate in good faith to replace such invalid, illegal and unenforceable provision (or portion of provision) with a
valid, legal and enforceable provision that achieves, to the greatest lawful extent under this Agreement, the economic, business and other purposes of such invalid, illegal or unenforceable provision (or portion of provision). This Agreement shall
not be invalidated by any future determination that any or all of the Licensed Patents have expired or been invalidated. 
 14.14
Assignment, Sage may not assign its rights or delegate its obligations under this Agreement, in whole or in part, by operation of law or otherwise, to any third party without the prior written consent of CyDex, which consent shall not be
unreasonably withheld. Notwithstanding the foregoing, Sage may assign its rights and delegate its obligations under this Agreement to an Affiliate or to a third party successor, whether by way of merger, sale of all or substantially all of its
assets, sale of stock or otherwise, without CyDex’s prior written consent. As a condition to any permitted assignment hereunder, the assignor must guarantee the performance of any assignee to the terms and obligations of this Agreement. Any
assignment by Sage not in accordance with this Section 14.14 shall be void. CyDex has the right to assign its rights or delegate its obligations under this Agreement, in whole or in part, by operation of law or otherwise, to any third
party, without any requirement for consent of Sage provided that CyDex also assigns all of its right, title and interest in all assets, including without limitation, intellectual property rights, pertaining to its Captisol business to the same third
party contemporaneous with the assignment of this Agreement. 
 14.15 Third Party Beneficiaries. Except for the rights of
Indemnified Parties pursuant to Section 10 hereof, and subject to Section 8.5 hereof, the terms and provisions of this Agreement are intended solely for the benefit of each party hereto and their respective successors or permitted
assigns and it is not the intention of the parties to confer third-party beneficiary rights upon any other person, including without limitation Sublicensees. The enforcement of any obligation of CyDex under this Agreement shall only be pursued by
Sage or such Indemnified Party, and not Sublicensees. 
 14.16 Remedies Cumulative. Except as provided in
Section 11, any enumeration of a party’s rights and remedies in this Agreement is not intended to be exclusive, and a party’s rights and remedies are intended to be cumulative to the extent permitted by law and include any
rights and remedies authorized in law or in equity. 
 14.17 Headings. The descriptive headings of this Agreement are
for convenience only, and shall be of no force or effect in construing or interpreting any of the provisions of this Agreement. 

14.18 Interpretation. The language used in this Agreement is die language chosen by the parties to express their mutual intent,
and no provision of this Agreement will be interpreted for or against any party because that party or its attorney drafted the provision. 

  
 28 

 ***Text Omitted and Filed Separately with the Securities and Exchange Commission
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 
  

 14.19 Counterparts. This Agreement may be executed in counterparts, each of
which shall constitute an original document, but both of which shall constitute one and the same instrument. 
 [Remainder of this
page left blank intentionally] 

  
 29 

 ***Text Omitted and Filed Separately with the Securities and Exchange Commission
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 
  

 IN WITNESS WHEREOF, the parties have executed this Commercial License Agreement as of
the Effective Date. 
  

			
	CYDEX PHARMACEUTICALS, INC.
		
	By:	 	/s/ Charles Berkman
		 	Name: Charles Berkman
		 	Title: VP and Secretary

  

			
	SAGE THERAPEUTICS, INC.
		
	By:	 	/s/ Kimi Iguchi
		 	Name: Kimi Iguchi
		 	Title: CFO

 August 21, 2013 

 ***Text Omitted and Filed Separately with the Securities and Exchange Commission
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 
  

 EXHIBIT A: CAPTISOL PATENTS 

[...***...] 

  
 [Exhibit continues on
next page] 
 A-1 

 ***Text Omitted and Filed Separately with the Securities and Exchange Commission
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 
  

 EXHIBIT B: LICENSED PRODUCT PATENTS 

[...***...] 

  
 B-1 

 ***Text Omitted and Filed Separately with the Securities and Exchange Commission
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 
  

 EXHIBIT C: SPECIFICATIONS 

[...***...] 

  
 C-1 

 ***Text Omitted and Filed Separately with the Securities and Exchange Commission
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 
  

 EXHIBIT D: SPECIFIED DILIGENCE REQUIREMENTS 

Sage is required to achieve the following milestones by the following respective deadline dates for Licensed Product: 

 

			
	Milestone	  	Achievement Date Deadline
	 	 
	 [...***...]
	  	[...***...]
	 	 
	 [...***...]
	  	[...***...]
	 	 
	 [...***...]
	  	[...***...]
	 	 
	 [...***...]
	  	[...***...]
	 	 
	 [...***...]
	  	[...***...]

  
 D-1 

 ***Text Omitted and Filed Separately with the Securities and Exchange Commission
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 
  

 EXHIBIT E: DOSING 

Dosing Matrix (Animals) 
 [...***...] 

  
 E-1 

 ***Text Omitted and Filed Separately with the Securities and Exchange Commission
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 
  

 AMENDMENT TO COMMERCIAL LICENSE AGREEMENT 

THIS AMENDMENT TO COMMERCIAL LICENSE
AGREEMENT (this “Amendment”) is made this 30th day of April, 2014 (the “Amendment Effective Date”) between: 

CYDEX PHARMACEUTICALS, INC., a Delaware corporation
(“CyDex”); and 
 SAGE THERAPEUTICS INC., a Delaware corporation
(“Sage”). 
 RECITALS 

WHEREAS, CyDex and Sage entered into a Commercial License Agreement (the “Agreement”) as
of August 21, 2013; 
 WHEREAS, CyDex and Sage wish to amend the Agreement in accordance with
Section 14.10 thereof, including by deleting the payment of $[...***...] upon the first submission of an IND, or an amendment to an IND, for a Probe Study (as defined in the Agreement prior to the Amendment Effective Date) and, instead,
requiring such amount, along with an additional $[...***...], to be paid in consideration of CyDex entering into this Amendment, as set forth below; 

NOW, THEREFORE, in consideration of the following mutual promises
and other good and valuable consideration, the receipt and sufficiency of which are acknowledged, the parties, intending to be legally bound, agree as follows: 

1. DEFINITIONS. 
 1.1
DEFINITIONS. All terms used, but not defined, in this Amendment shall have the meaning set forth in the Agreement. 

1.2 AMENDED DEFINITIONS. The following definitions are hereby amended to read as follows: 

“Field” means the treatment, diagnosis or prevention of any disease or symptom in humans or animals, including the Epilepticus
Field, the TBI Field and each Additional Subfield. 
 “Pfizer” means Pfizer Inc. 

“Probe Study” means the conduct of a human study (excluding any Phase III Study or Pivotal Study) of a Licensed Product in
and for an Additional Subfield in fewer than fifty (50) subjects. 
 1.3 ADDITIONAL DEFINITIONS.
The following definitions are added to Section 1 of the Agreement: 
 “Additional Subfield” means each disease or
symptom in humans or animals that is not a Primary Subfield; for clarity, an Expansion to a particular Additional Subfield is not a separate Additional Subfield. 

  

	
	AMENDMENT TO COMMERCIAL LICENSE AGREEMENT

 ***Text Omitted and Filed Separately with the Securities and Exchange Commission
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 
  

 “Epilepticus Field” means the field of therapeutic use against status
epilepticus in humans. 
 “Expansion” means, with respect to a particular Additional Subfield for which a clinical study
was conducted, an NDA was filed or Marketing Approval was obtained, an additional clinical study, or receipt of NDA or Marketing Approval, of the Licensed Product in such Additional Subfield for a different subpatient population, line of therapy or
new use as a monotherapy or in combination with another treatment or drug, other than the population, line of therapy or use for which the prior clinical study(ies) were conducted, NDA was filed or Marketing Approval was received. 

“Phase II Study” means the conduct of a human study, as described in 21 C.F.R. §312.21(b) and its foreign equivalents,
of a Licensed Product, but excluding any Probe Study. 
 “Phase III Study” means the conduct of a human study, as described
in 21 C.F.R. §312.21(c) and its foreign equivalents, of a Licensed Product. 
 “Pivotal Study” means a controlled
pivotal clinical study of a Licensed Product that is prospectively designed to demonstrate statistically whether such Licensed Product is effective and safe for use in a particular indication in a manner sufficient to obtain Marketing Approval to
market such product in the United States, China, Japan or Germany (via the European Union (including the European Medicines Authority) or otherwise). 

“Primary Subfield” means each of the following: the Epilepticus Field or the TBI Field. 

“Subfield” means each Primary Subfield, on a Primary Subfield-by-Primary Subfield basis, and each Additional Subfield, on an
Additional Subfield-by-Additional Subfield basis. 
 “TBI Field” means the treatment of traumatic brain injury in humans.

 1.4 DELETED DEFINITIONS. The definitions of “Probe Condition” and
“Probe Study Product”, and all references thereto, are hereby deleted from the Agreement. 
 2. PROBE
STUDY LICENSE. Section 2.1(b) of the Agreement is hereby amended to read: 
 (b)
[Intentionally Omitted]. 
 3. NEGATIVE COVENANT. Section 2.1(e) of the Agreement is
hereby amended to read: 
 (e) Negative Covenant. During the term of this Agreement, CyDex and its Affiliates shall not grant
any rights to any Third Party that conflict with the exclusive rights granted herein to Sage or that conflict with or otherwise impair Sage’s ability to conduct the activities described herein. Without limiting the generality of the foregoing,
in the event that CyDex or any of its Affiliates become aware that a Third Party is conducting research, development or commercial activities using the Compound with Captisol, then CyDex shall take all reasonable measures to cease the supply of
Captisol to such Third Party and to any other Third Party that is determined to be supplying Captisol to such Third Party. 

  

	
	AMENDMENT TO COMMERCIAL LICENSE AGREEMENT

 ***Text Omitted and Filed Separately with the Securities and Exchange Commission
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 
  

 4. PAYMENTS.  

4.1 Section 4.1(a)(ii) of the Agreement is hereby amended to read: 

(ii) CyDex acknowledges receipt of the payment of $300,000 on the Effective Date. 

4.2 In consideration of CyDex entering into this Amendment, Sage agrees to pay to CyDex $200,000 on the Amendment Effective Date. 

4.3 Section 4.1(b) of the Agreement is hereby amended to read: 

(b) Milestone Payments.  

(i) Epilepticus Field and TBI Field. Within [...***...] days following the occurrence of each of the milestone events listed
below with respect to the Licensed Product in either Primary Subfield, Sage shall provide written notice to CyDex of the achievement of such milestone event, and within [...***...] days of the occurrence of each of the milestone events, pay to
CyDex the applicable non-refundable milestone fee listed next to each such event in further consideration of the rights granted Sage hereunder. The milestone payments (each payable only one time per each of the Primary Subfields, regardless of the
number of times achieved by the Licensed Product for such Primary Subfield; for the avoidance of doubt, if the same Licensed Product first achieves one or more given milestones for both the Epilepticus Field and the TBI Field, then the milestone
payment for that event must be paid twice; and in no event shall the maximum payment under this Section 4.1(b)(i) exceed $[...***...]) are as follows. If any such milestone is achieved in the relevant Primary Subfield before all prior
sequential milestones have been actually achieved in such Primary Subfield, then any and all prior sequential milestones which were not previously actually achieved shall be deemed to have thereby been achieved with respect to such Primary Subfield,
and the milestone payments for such deemed-achieved milestones shall also be payable with respect to such Primary Subfield within such [...***...] days. 
  

					
	 	  	 MILESTONE ACHIEVED IN THE RELEVANT
PRIMARY SUBFIELD
	  	MILESTONE
PAYMENT
	(i)	  	[...***...]	  	$[...***...]
	(ii)	  	[...***...]	  	$[...***...]
	(iii)	  	[...***...]	  	$[...***...]
	(iv)	  	[...***...]	  	$[...***...]

 (ii) Additional Subfields. Within [...***...] days following the occurrence of each of the
milestone events listed below with respect to the Licensed Product in an Additional Subfield, Sage shall provide written notice to CyDex of the achievement of such milestone event, and within [...***...] days of the occurrence of each of the
milestone events, pay to CyDex the applicable non-refundable milestone fee listed next to each such event in further consideration of the rights granted Sage hereunder. The milestone payments (each payable only one time per each of the first two
(2) Additional Subfields, regardless of the number of times achieved by the Licensed Product for such Additional Subfield; for the  

  

	
	AMENDMENT TO COMMERCIAL LICENSE AGREEMENT

 ***Text Omitted and Filed Separately with the Securities and Exchange Commission
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 
  

 
avoidance of doubt, if the same Licensed Product first achieves one or more given milestones for two Additional Subfields, then the milestone payment for that event must be paid twice; and in no
event shall the maximum payment under this Section 4.1(b)(ii) exceed $[...***...]) are as follows. Subject to the preceding sentence, if any such milestone is achieved in the relevant Additional Subfield before all prior sequential
milestones have been actually achieved in such Additional Subfield, then any and all prior sequential milestones which were not previously actually achieved with respect to such Additional Subfield shall be deemed to have thereby been achieved, and
the milestone payments for such deemed-achieved milestones shall also be payable with respect to such Additional Subfield within such [...***...] days. 
  

					
	 	  	 MILESTONE
	  	MILESTONE
PAYMENT
	(i)	  	[...***...]	  	$[...***...]
	(ii)	  	[...***...]	  	$[...***...]
	(iii)	  	[...***...]	  	$[...***...]
	(iv)	  	[...***...]	  	$[...***...]

 4.4 Section 4.1(d) of the Agreement is hereby deleted in its entirety. 

5. DILIGENCE. The penultimate sentence of Section 6.1 of the Agreement is hereby amended to read: 

For clarity, Sage may meet the requirements of this Section 6.1 through its activities with respect to the Licensed Product in just
one of the Subfields. 
 6. REPRESENTATIONS AND WARRANTIES. CyDex represents and warrants
to Sage (as of the Amendment Effective Date) as follows: 
 (i) Neither it nor any of its Affiliates has entered into any
agreement with any third party (including any Pre-Existing Agreement) that is in conflict with the rights granted to Sage pursuant to this Agreement; and 

(ii) Neither CyDex nor any of its Affiliates has granted any Affiliate of CyDex or any Third Party any rights to develop or
commercialize any pharmaceutical composition comprising the Compound combined with or formulated using Captisol. 
 7.
INDEMNIFICATION. Section 10.1(c) is hereby amended to read: 
 (c) CyDex’s breach of this
Agreement, including without limitation any of its representations and warranties set forth in Sections 9.1 and 9.2 of the Agreement or in Section 6 of the Amendment, 

8. INTERPRETATION. The following sentence is added to the end of Section 14.18 of the Agreement: 

Except as the context otherwise requires, (a) the word “including” or correlatives thereof, means “including without
limitation,” and (b) the word “or” means “and/or.” 

  

	
	AMENDMENT TO COMMERCIAL LICENSE AGREEMENT

 ***Text Omitted and Filed Separately with the Securities and Exchange Commission
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 
  

 9. ENTIRE AGREEMENT/AMENDMENTS. Except as
amended by this Amendment, the Agreement shall remain in full force and effect. After the Amendment Effective Date, every reference in the Agreement to the “Agreement” shall mean the Agreement as amended by this Amendment. 

10. Counterparts. This Amendment may be executed in counterparts, each of which shall constitute an original document, but both of which shall
constitute one and the same instrument.  
 [Remainder of this page left blank intentionally] 

  

	
	AMENDMENT TO COMMERCIAL LICENSE AGREEMENT

 ***Text Omitted and Filed Separately with the Securities and Exchange Commission
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 
  

 IN WITNESS WHEREOF, the parties have executed this Amendment to Commercial License
Agreement as of the Amendment Effective Date. 
  

			
	CYDEX PHARMACEUTICALS, INC.
		
	By:	 	/s/ Charles Berkman

			
	Name:	 	Charles Berkman
	Title:	 	VP and Secretary

  

			
	SAGE THERAPEUTICS, INC.
		
	By:	 	/s/ Jeffrey Jonas

			
	Name:	 	Jeffrey Jonas
	Title:	 	CEO

  

	
	AMENDMENT TO COMMERCIAL LICENSE AGREEMENTEX-10.5

 Exhibit 10.5 

***Text Omitted and Filed Separately with the Securities and Exchange Commission Confidential Treatment Requested Under 17 C.F.R. Sections
200.80(b)(4) and 230.406 
 Non-Exclusive License Agreement 

between 
 The Regents of
the University of California 
 and 

Sage Therapeutics, Inc. 

for 
 Allopregnanolone in
the Treatment of Status Epilepticus and Post-Partum Depression 
 File No. [...***...] 

 ***Text Omitted and Filed Separately with the Securities and Exchange Commission
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 
  

 Table of Contents 

 

							
	 	 	 	  	Page	 
	 1.
	 	DEFINITIONS	  	 	2	  
			
	 2.
	 	GRANT; RESTRICTIONS	  	 	3	  
			
	 3.
	 	SUBLICENSES	  	 	5	  
			
	 4.
	 	MATERIAL FEE	  	 	5	  
			
	 5.
	 	ROYALTIES AND MILESTONES	  	 	5	  
			
	 6.
	 	DILIGENCE	  	 	6	  
			
	 7.
	 	PROGRESS AND ROYALTY REPORTS	  	 	6	  
			
	 8.
	 	BOOKS AND RECORDS	  	 	7	  
			
	 9.
	 	LIFE OF THE AGREEMENT	  	 	8	  
			
	 10.
	 	TERMINATION BY THE REGENTS	  	 	8	  
			
	 11.
	 	TERMINATION BY LICENSEE	  	 	10	  
			
	 12.
	 	DISPOSITION OF MATERIAL, MODIFICATIONS AND DERIVED PRODUCTS ON HAND UPON TERMINATION	  	 	10	  
			
	 13.
	 	USE OF NAMES AND TRADEMARKS	  	 	10	  
			
	 14.
	 	LIMITED WARRANTIES	  	 	11	  
			
	 15.
	 	INDEMNIFICATION	  	 	12	  
			
	 16.
	 	COMPLIANCE WITH LAWS/EXPORT CONTROLS	  	 	13	  
			
	 17.
	 	GOVERNMENT APPROVAL OR REGISTRATION	  	 	14	  
			
	 18.
	 	ASSIGNMENT	  	 	14	  
			
	 19.
	 	NOTICES	  	 	14	  
			
	 20.
	 	PAYMENTS	  	 	15	  
			
	 21.
	 	WAIVER	  	 	15	  
			
	 22.
	 	CONFIDENTIALITY	  	 	15	  
			
	 23.
	 	PUBLICATION OF RESEARCH USE RESULTS AND ACKNOWLEDGEMENT	  	 	16	  
			
	 24.
	 	DISCLOSURE, INVENTORSHIP, AND INTELLECTUAL PROPERTY RIGHTS	  	 	17	  
			
	 25.
	 	FORCE MAJEURE	  	 	17	  
			
	 26.
	 	SEVERABILITY	  	 	18	  
			
	 27.
	 	APPLICABLE LAW; VENUE; ATTORNEYS’ FEES	  	 	18	  
			
	 28.
	 	SCOPE OF AGREEMENT	  	 	18	  

 ***Text Omitted and Filed Separately with the Securities and Exchange Commission
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 
  

 Non-Exclusive License Agreement 

for 
 Allopregnanolone in
the Treatment of Status Epilepticus 
 and Post-Partum Depression 

(File No. [...***...]) 

This non-exclusive license agreement (“Agreement”) is effective this 23rd day of October 2013 (“Effective Date”), by and
between The Regents of the University of California (“The Regents”), a California corporation, having its statewide administrative offices at 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200, as represented by its Davis
campus, having an address at UC Davis InnovationAccess, 1850 Research Park Drive, Suite 100, Davis, California 95618 and Sage Therapeutics, Inc. (“Licensee”), a Delaware corporation, having a principal place of business at 215 First
Street, Cambridge, Massachusetts 02142. The Regents and Licensee will be referred to herein, on occasion, individually as “Party” or collectively as “Parties.” 

RECITALS 
 Whereas, the
Material (defined below) was made at the University of California, Davis campus (“UC Davis”) by Dr. Michael Rogawski (“Investigator”); 

Whereas, the development of the Material was sponsored in part by one or more agencies of the United States Government; accordingly, under
Federal law, the Material is tangible research product owned by The Regents; also, any related invention rights are subject to the rights of the United States Government under 35 USC §§ 200-212 and implementing regulations; and The Regents
is obligated to grant to the United States Government a non-exclusive, non-transferable, irrevocable, paid-up license to use the Material by or on behalf of the United States Government throughout the world; 

Whereas, Licensee has requested from The Regents the Material as defined in Paragraph 1.1 below for the Research Use defined in Paragraph
1.6(ii) below, which Material was developed with the Department of Defense support under contract number W81XWH-09-1-0746 administered by the USA Med Research ACQ Activity; 

Whereas, The Regents and Licensee have entered into a Letter Agreement (UC Agreement Control No. 2013-30-0469) effective March 12,
2013 (“Letter Agreement”) for the purpose of granting Licensee an exclusive right to negotiate an exclusive license; 
 Whereas,
The Regents and Licensee entered into an Investigational New Drug Application (“IND”) Data Transfer Agreement (UC Agreement Control No. 2013-210514) effective April 1, 2013 (“IND Data Transfer Agreement”) for the
purpose of reference of data in Licensee’s pre-IND interactions with the Food and Drug Administration (“FDA”) in advance of a submission of Licensee’s IND application for use of Allopregnanolone for the treatment of status
epilepticus and pre-IND discussion pertaining to an IND application for such indication with the FDA; 

 ***Text Omitted and Filed Separately with the Securities and Exchange Commission
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 
  

 Whereas, The Regents and Licensee entered into a Material Transfer Agreement (File
No. 2013-816-M) effective July 9, 2013 (“MTA”) for the purpose of The Regents to transfer a portion of the Material, Allopregnanolone (GMP grade chemical), to Licensee for developing a clinically relevant formulation for
treatment of status epilepticus, such use limited to formulation/process development (prototype batch, material compatibility, filter study validation); engineering batch manufacture; and analytical support (re-release of API); 

Whereas, The Regents and Licensee desire to have the Data (defined below) and Material (defined below) used by Licensee so that products
resulting therefrom may be developed, commercialized and available for public use and benefit; and 
 Whereas, Licensee desires to acquire,
and The Regents desires to grant, a license under Property Rights in accordance with the terms herein. 
 Now, therefore, the Parties agree as follows: 

1. DEFINITIONS 
  

	1.1	“Material” means approximately [...***...] kilograms of Allopregnanolone (GMP grade chemical), approximately [...***...] grams of which was provided to Licensee prior to the Effective Date pursuant
to the MTA. 

  

	1.2	“Modifications” mean substances created or made by or on behalf of the Licensee that either contain or incorporate the Material or were otherwise created through the use of the Material. For the purpose under
this Agreement, pharmaceutical formulations of Material shall be considered Modifications. Notwithstanding the above, Licensee shall not chemically modify or alter the chemical structure of the Material. 

 

	1.3	“Data” means the confidential Investigational New Drug (IND) application package (IND Number 111,085) owned by The Regents and generated by the The Regents’ Investigator for the use of Allopregnanolone
for Traumatic Brain Injury and any updates to such IND. 

  

	1.4	“Derived Product” means a product containing Allopregnanolone produced by or on behalf of Licensee for Sale or Sold as a drug for status epilepticus and/or post-partum depression. 

 

	1.5	“Property Rights” means all personal proprietary rights of The Regents covering the tangible personal property in the Data and Material. 

 

	1.6	“Licensed Field of Use” means the (a) use of Data for Reference Use as defined below and (b) use of Material or Modifications for Research Use as defined below. 

(i) “Reference Use” means use of Data by the Licensee, and by affiliates, contractors, consultants, agents and/or vendors on behalf
of Licensee, for the sole purpose of reference or incorporation to the extent that such reference or incorporation identifies, labels it as an excerpt from Data and acknowledges UC Davis as the source of the Data in Licensee’s IND
application(s) with the FDA for use of Allopregnanolone for the treatment of status epilepticus and/or postpartum depression. [...***...]. 

  
 2 

 ***Text Omitted and Filed Separately with the Securities and Exchange Commission
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 
  

 (ii) “Research Use” means use of Material or Modifications to develop a clinically
relevant pharmaceutical formulation and use of such pharmaceutical formulation for FDA-approved human clinical trials for treatment of status epilepticus and/or post-partum depression. Research Use includes transfer of Material by Licensee to a
third party who uses such Material to create a Modification on behalf of Licensee. 
  

	1.7	“Sale” means, for Derived Products, the act of selling, leasing or otherwise transferring, providing, or furnishing such product for any consideration. Correspondingly, “Sell” means to make or cause
to be made a Sale, and “Sold” means to have made or caused to be made a Sale. 

  

	1.8	“Net Sales” means the gross invoice price charged by, and the value of any noncash consideration owed to, Licensee for Sales of Derived Products in the Licensed Territory, less the sum of the following actual
and customary deductions where applicable: cash, trade or quantity discounts; sales, use, tariff, ^import/export duties or other excise taxes when included in gross sales, but not value-added taxes assessed or income taxes derived from such
sales; transportation and related freight/shipping insurance charges; and allowances or credits to customers because of rejections or returns. 

  

	1.9	“Licensed Territory” means the United States of America and its territories and possessions, and any foreign countries where Property Rights exist. 

 

	1.10	“Research Use Results” means all technical information and data relating to the Licensed Field of Use. 

2. GRANT; RESTRICTIONS 
  

	2.1	Subject to the limitations set forth in this Agreement, including without limitation the licenses granted to the United States Government referred to in the Recitals above and the rights reserved in Paragraphs 2.3 and
2.7 below, The Regents hereby grants to Licensee a non-exclusive license under Property Rights, in the Licensed Territory, to the extent such license rights may be lawfully granted, to (a) use Data for the Reference Use under the Licensed Field
of Use in compliance with all applicable statutes and regulations, and (b) possess and use Material or Modifications solely for Research Use. 

  

					
	2.2	 	(a)	  	The rights granted to Licensee under Paragraph 2.1 above are limited for the purposes stated in this Agreement. Any other use of Data, Material or Modifications is expressly prohibited.
			
		 	(b)	  	Licensee agrees to use Material or Modifications in compliance with all applicable statutes and regulations, including, but not limited to, those related to research involving the use of humans, animals or recombinant DNA. The
Material or Modifications will not be used by Licensee for commercial purposes or any other use other than the Research Use (provided that the use of Materials

  
 3 

 ***Text Omitted and Filed Separately with the Securities and Exchange Commission
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 
  

					
			
		 		  	or Modifications to develop a clinically relevant pharmaceutical formulation, use of such pharmaceutical formulation for FDA-approved human clinical trials, for the purposes of eventual commercial sale of such pharmaceutical
formulation, shall not be considered a use for commercial purposes).
			
		 	(c)	  	Licensee shall not analyze the Material for chemical composition or physical structure or have or allow any component of the Material to be analyzed or make any use of any such analysis other than for quality testing purposes to
meet FDA submission requirements. Licensee shall not make chemical modification or alter the chemical structure of the Material in any way except as pursuant to Paragraph 1.6.

  

	2.3	The Regents reserves the right to do any one or more of the following: 

  

	 	(a)	publish any technical data resulting from research performed by The Regents relating to the Data and Material; 

  

	 	(b)	make and use the Data and Material and associated technology for educational and research purposes; 

  

	 	(c)	practice Property Rights for educational and research purposes, including in order to make and use products; 

  

	 	(d)	allow other educational and non-profit institutions to do any one or more of the activities of Subparagraphs 2.3 (a), (b), and (c) above, for educational and research purposes; and 

 

	 	(e)	transfer or grant rights in the Data and Material as further described in Paragraph 2.7. 

  

	2.4	The Regents, through the Investigator, will endeavor to transfer to Licensee, the remaining amount (approximately [...***...] grams) of the Material within fourteen (14) days from the date this Agreement is
executed by The Regents and Licensee shall pay all the storage, handling, associated shipping costs and incidental expenses, which shall be included in (and not separate from) the Material Fee (defined below). Licensee acknowledges that The Regents,
through the Investigator, has transferred a portion of Material to Licensee in accordance with the terms and conditions of the MTA. The Material will be delivered to: 

[...***...] 
  

	2.5	The Regents is not obligated to provide any replacements or any additional amounts of Material. 

  

	2.6	 Except as otherwise permitted under this Agreement, Licensee will not Sell, donate, abandon, or otherwise transfer Data to any third party and will
not Sell, donate, abandon, or otherwise transfer ownership of Material to any third party. Licensee acknowledges that The Regents retains ownership of Data and that ownership of Data is not transferred

  
 4 

 ***Text Omitted and Filed Separately with the Securities and Exchange Commission
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 
  

	 	
to Licensee under this Agreement. However, ownership (title) of the Material will transfer to Licensee upon receipt by Licensee. For such Material that has title transferred to Licensee, such
Material will otherwise remain as Material under this Agreement and all other terms of this Agreement will apply. 

  

	2.7	The Regents is free to transfer or grant rights in the Data to third parties for any purposes. 

3. SUBLICENSES 
  

	3.1	This Agreement specifically excludes the right of Licensee to issue sublicenses. 

 4.
MATERIAL FEE 
  

	4.1	Licensee will pay to The Regents a sum of [...***...] Dollars ($[...***...]) for the costs of storage, packaging, transport and incidental expenses for the Material (“Material Fee”).

  

	4.2	The Material Fee is due fifteen (15) days after receipt of an invoice therefor. The Material Fee is non-creditable, non-refundable and not an advance against royalties or other payments due under this Agreement.

 5. ROYALTIES AND MILESTONES 
  

	5.1	Licensee will pay to The Regents earned royalties (“Earned Royalties”) at the rate of [...***...] percent ([...***...]%) of the Net Sales in the Licensed Territory of each Derived Product for
fifteen (15) years after first Sale of each such Derived Product. 

  

	5.2	Earned Royalties accruing to The Regents will be paid to The Regents semiannually within [...***...] days after the end of each [...***...] month period as follows: November 1 (for the [...***...]
month period commencing March 1 of that year), and May 1 (for the [...***...] month period commencing September 1 of the prior calendar year). 

 

	5.3	All consideration due The Regents will be payable in United States dollars. When Derived Products are Sold for monies other than United States dollars, the Earned Royalties will first be determined in the foreign
currency of the country in which the Sale was made and then converted into equivalent United States dollars. The exchange rate will be that quoted in the Wall Street Journal on the last business day of the reporting period. 

 

	5.4	Payments due for Sales occurring in any country outside the United States will not be reduced by any taxes, fees, or other charges imposed by the government of such country on the remittance of royalty income. Licensee
will also be responsible for all bank transfer charges. 

  

	5.5	Licensee will make all payments under this Agreement either by check or electronic transfer, payable to “The Regents of the University of California” and Licensee will forward such payments to The Regents at
the address shown in Paragraph 20.1 below. 

  
 5 

 ***Text Omitted and Filed Separately with the Securities and Exchange Commission
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 
  

	5.6	No Earned Royalties will be collected or paid hereunder on Sales of Derived Products to, or for use by, the United States Government. Licensee will reduce the amount charged for such Sales by an amount equal to the
Earned Royalties otherwise due The Regents as provided herein. 

  

	5.7	(a) Within [...***...] days after the [...***...], whichever occurs first, Licensee will pay to The Regents a one-time, non-refundable and non-creditable milestone fee of [...***...] dollars
($[...***...]). 

 (b) Within [...***...] days after the [...***...], whichever occurs second and for which a
milestone fee was not paid under Paragraph 5.7(a), Licensee will pay to The Regents a onetime, non-refundable and non-creditable milestone fee of [...***...] dollars ($[...***...]). 

(c) For clarity, the milestone fees in clauses (a) and (b) above shall each be payable only once, [...***...]. 

6. DILIGENCE 
  

	6.1	Licensee, upon execution of this Agreement, will use commercially reasonable efforts to proceed with the development, manufacture, and Sale of one or more Derived Products and will use commercially reasonable efforts to
market such Derived Products in quantities sufficient to meet the market demand. 

  

	6.2	In addition to its obligations under Paragraph 6.1, Licensee specifically commits to obtain all necessary governmental approvals in each country where Derived Products are made, manufactured, used, Sold, imported, or
offered for Sale. 

  

	6.3	If Licensee is unable to meet any of its diligence obligations set forth in Paragraphs 6.1 and 6.2, then The Regents will have the right and option to terminate this Agreement in accordance with Paragraph 10.1 below.

 7. PROGRESS AND ROYALTY REPORTS 
  

	7.1	For the period beginning January 1, 2014, within sixty (60) days after each subsequent June 30 and December 31, Licensee will submit to The Regents a semi-annual progress report covering
Licensee’s Research Use Results and the test conditions used, activities related to the development and testing of all Derived Products, and the obtaining of necessary governmental approvals, if any, for marketing Derived Products in the United
States. These progress reports will be made for all development activities. If Licensee fails to submit a timely progress report to The Regents, The Regents will be entitled to terminate this Agreement in accordance with Paragraph 10.1 below. If
either Party terminates this Agreement before any Derived Products are Sold or before this Agreement’s expiration, a final progress report covering the period prior to termination must be submitted within thirty (30) days of termination.

  
 6 

 ***Text Omitted and Filed Separately with the Securities and Exchange Commission
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 
  

	7.2	Each progress report will be a sufficiently detailed summary of activities of Licensee so that The Regents may evaluate and determine Licensee’s progress in the development of Derived Product and Research Use, and
in meeting its diligence obligations under Article 6, and will include (but not be limited to) the following: summary of work completed and in progress; current schedule of anticipated events and milestones; and anticipated market introduction
dates. 

  

	7.3	In Licensee’s progress report immediately subsequent to the first Sale by Licensee of Derived Products, Licensee will report the date of such first Sale. 

 

	7.4	After the first Sale of a Derived Product, Licensee will provide semi-annual royalty reports to The Regents on or before November 1 (for the six (6)-month period commencing March 1 of that year), and
May 1 (for the six (6)-month period commencing September 1 of the prior calendar year). Each such royalty report will include at least the following: 

  

	 	(a)	The number of Derived Products manufactured and the number of Derived Products Sold; 

  

	 	(b)	Gross revenue from Sale of Derived Products; 

  

	 	(c)	Net Sales pursuant to Paragraph 1.8; 

  

	 	(d)	Itemized deductions pursuant to Paragraph 1.8; 

  

	 	(e)	Listing of distributors Selling Derived Products; and 

  

	 	(f)	Total Earned Royalties due to The Regents. 

  

	7.5	If no Sales of Derived Product have occurred during the reporting period, a statement to this effect is required in the royalty report for that period. 

8. BOOKS AND RECORDS 
  

	8.1	Licensee will keep full, true, and accurate books of accounts containing all particulars that may be necessary for the purpose of showing the amount of Earned Royalties payable to The Regents and Licensee’s
compliance with other obligations under this Agreement. Said books of accounts will be kept at Licensee’s principal place of business or the principal place of business of the appropriate division of Licensee to which this Agreement relates.
Said books and the supporting data will be open at all reasonable times during normal business hours upon at least ten (10) business days’ notice, for five (5) years following the end of the calendar year to which they pertain, to the
inspection and audit by representatives of The Regents reasonably acceptable to Licensee for the purpose of verifying Licensee’s royalty statement or compliance in other respects with this Agreement. Such representatives will be bound to hold
all information in confidence except as necessary to communicate Licensee’s noncompliance with this Agreement to The Regents. The Regents may conduct such an inspection and audit only once in any twelve (12)-month period, and may not conduct
such an inspection and audit with respect to the same time period more than once. 

  
 7 

 ***Text Omitted and Filed Separately with the Securities and Exchange Commission
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 
  

	8.2	The fees and expenses of The Regents’ representatives performing such an examination will be borne by The Regents. However, if an error in underpaid royalties to The Regents of more than five percent (5%) of
the total Earned Royalties due for any year is discovered, then the fees and expenses of these representatives will be borne by Licensee. 

9. LIFE OF THE AGREEMENT 
  

	9.1	This Agreement shall be effective as of the Effective Date and unless terminated earlier pursuant to Article 6, Article 10, Article 11 or Article 25, this Agreement shall continue in effect until fifteen (15) years
after the last-to-occur first Sale of a Derived Product (the effective period of the Agreement being referred to herein as the “Term”). Notwithstanding the foregoing, in no event will the Term extend beyond twenty-seven (27) years
after the Effective Date. Upon expiration of this Agreement, the license set forth in Paragraph 2.1 shall become perpetual, irrevocable, royalty-free and fully paid-up, subject to Paragraph 9.2. 

 

	9.2	Any termination or expiration of this Agreement will not affect the rights and obligations set forth in the following Articles: 

  

					
		 	Article 1	  	Definitions
		 	Article 8	  	Books and Records
		 	Article 9	  	Life of the Agreement
		 	Article 12	  	Disposition of Material, Modifications, and Derived Products on Hand upon Termination
		 	Article 13	  	Use of Names and Trademarks
		 	Article 14	  	Limited Warranties
		 	Article 15	  	Indemnification
		 	Article 19	  	Notices
		 	Article 20	  	Payments
		 	Article 22	  	Confidentiality
		 	Article 27	  	Applicable Law; Venue; Attorneys’ Fees
		 	Article 28	  	Scope of Agreement

  

	9.3	The termination or expiration of this Agreement will not relieve Licensee of its obligation to pay any monies owing at the time of such termination or expiration and will not relieve any obligations, of either Party to
the other Party, established prior to termination or expiration. 

 10. TERMINATION BY THE REGENTS 

 

	10.1	If Licensee should violate or fail to perform any material term of this Agreement, then The Regents may give written notice of such default (“Notice of Default”) to Licensee. If Licensee should fail to repair
such default in accordance with Paragraph 10.3 and, if applicable, Paragraph 10.4, The Regents will have the right to terminate this Agreement and the license herein by providing a second written notice (“Notice of Termination”) to
Licensee. If a Notice of Termination is sent to Licensee, this Agreement will automatically terminate on the effective date of such notice. Such termination will not relieve Licensee of its obligation to pay any royalty or fees owing at the time of
such termination and will not impair any accrued rights of The Regents. These notices will be subject to Article 19 (Notices). 

  
 8 

 ***Text Omitted and Filed Separately with the Securities and Exchange Commission
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 
  

	10.2	Notwithstanding Paragraph 10.1 above, this Agreement will automatically terminate in the event of Licensee’s insolvency or the filing of a petition for relief under the United States Bankruptcy Code
(a) by Licensee as a debtor or (b) against Licensee as an alleged debtor, if such petition against Licensee has not been stayed or dismissed within sixty (60) days after filing. 

 

	10.3	After The Regents has given the Notice of Default, and if Licensee fails to repair such default within sixty (60) days after the effective date of such notice, if the Parties can mutually agree, no later than one
hundred twenty (120) days after the effective date of the Notice of Default as to the measures Licensee is to take to adequately address the material term that has been breached by Licensee, then this Agreement will not terminate subject to
Licensee’s performance of such measures. If the Parties are unable to mutually agree on the measures Licensee is to take to address the material breach, then the Parties will submit the dispute to an unrelated third party arbitrator to
determine the measures Licensee is to take to address the material breach, in accordance with Paragraph 10.4 (“Baseball Arbitration”). 

  

	10.4	 Any Baseball Arbitration shall be held in San Francisco, California, according to the then-current commercial arbitration rules of the American
Arbitration Association (“AAA”), except to the extent such rules are inconsistent with this Paragraph 10.4. The Baseball Arbitration will be conducted by one (1) arbitrator who shall be reasonably acceptable to the Parties and who
shall be appointed in accordance with AAA rules. If the Parties are unable to select an arbitrator, then the arbitrator shall be appointed in accordance with AAA rules. Any arbitrator chosen hereunder shall have educational training and industry
experience sufficient to demonstrate a reasonable level of experience relevant to the nature of the matter in dispute. Within twenty (20) days after the selection of the arbitrator, each Party shall submit to the arbitrator and the other Party
a proposal for the steps Licensee is to take to address the material breach, together with any relevant evidence in support thereof (the “Proposals”). Within fifteen (15) days after the delivery of the last Proposal to the arbitrator,
each Party may submit a written rebuttal of the other Party’s Proposal and may also amend and re-submit its original Proposal. The Parties and the arbitrator shall meet within fifteen (15) days after the Parties have submitted their
Proposals, at which time each Party shall have one (1) hour to argue in support of its Proposal. The Parties shall not have the right to call any witnesses in support of their arguments, nor compel any production of documents or take any
discovery from the other Party in preparation for the meeting. Within thirty (30) days after such meeting, the arbitrator shall select one of the Proposals so submitted by one of the Parties as the resolution of the dispute, but may not alter
the terms of either Proposal and may not resolve the dispute in a manner other than by selection of one of the submitted Proposals. If a Party fails to submit a Proposal within the initial twenty (20) day time frame set forth above, the
arbitrator shall select the Proposal of the other Party as the determination of the steps Licensee shall take to remedy the material breach. Any time period set forth in this Paragraph 10,4 may be extended by mutual agreement of the Parties. The
content (but not 

  
 9 

 ***Text Omitted and Filed Separately with the Securities and Exchange Commission
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 
  

	 	
the existence or outcome) of the proceedings shall be confidential. Each Party shall bear its own costs incurred in Baseball Arbitration, and Licensee shall pay the costs of the arbitrator. The
Regents shall have the right to issue the Notice of Termination in respect of the applicable material breach following Baseball Arbitration only if Licensee fails to perform the measures to address such material breach as set forth in the Proposal
selected by the arbitrator. 

 11. TERMINATION BY LICENSEE 

 

	11.1	Licensee will have the right at any time to terminate this Agreement by giving notice in writing to The Regents. Such notice of termination will be subject to Article 19 (Notices) and termination of this Agreement will
be effective sixty (60) days after the effective date of such notice. 

  

	11.2	Any termination pursuant to Paragraph 11.1 will not relieve Licensee of any obligation or liability accrued hereunder prior to such termination or rescind anything done by Licensee or any payments made to The Regents
hereunder prior to the time such termination becomes effective, and such termination will not affect in any manner any rights of The Regents arising under this Agreement prior to such termination. 

12. DISPOSITION OF MATERIAL, MODIFICATIONS AND DERIVED PRODUCTS 

ON HAND UPON TERMINATION 
  

	12.1	Upon termination of this Agreement, for a period of one hundred and twenty (120) days after the date of termination, Licensee may complete and Sell any partially made Derived Products; provided that all such Sales
will be subject to the terms of this Agreement including, but not limited to, the payment of Earned Royalties and the rendering of royalty reports thereon. Licensee may not otherwise make, have made, use, Sell, have Sold, offer for Sale, or import
Derived Products after the date of termination. 

  

	12.2	Upon termination of this Agreement for any reason, Licensee will destroy any Material or Modifications in its possession within fifteen (15) days following the effective date of termination. Licensee will provide
The Regents within thirty (30) days following said termination date with written notice that the Material and Modifications have been destroyed. 

13. USE OF NAMES AND TRADEMARKS 
  

	13.1	Nothing contained in this Agreement will be construed as conferring any right to use in advertising, publicity or other promotional activities any name, trademark, trade name, or other designation of either Party by the
other (including any contraction, abbreviation, or simulation of any of the foregoing). Unless required by law or consented to in writing by The Regents, the use by Licensee of the name “The Regents of the University of California” or the
name of any University of California campus in advertising, publicity or other promotional activities (other than as set forth in Paragraph 23.1) is expressly prohibited. 

  
 10 

 ***Text Omitted and Filed Separately with the Securities and Exchange Commission
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 
  

 14. LIMITED WARRANTIES 

 

	14.1	The Regents warrants to Licensee that it has the lawful right to grant this license. 

  

	14.2	This license and the associated Property Rights and Material are provided WITHOUT WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER WARRANTY, EXPRESS OR IMPLIED. THE REGENTS MAKES NO
REPRESENTATION OR WARRANTY THAT THE PROPERTY RIGHTS, DATA, MATERIAL, MODIFICATIONS OR DERIVED PRODUCTS, WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK OR OTHER PROPRIETARY RIGHT. 

 

					
	14.3	 	(a)	  	EXCEPT FOR LICENSEE’S OBLIGATIONS REGARDING CLAIMS OF THIRD PARTIES PURSUANT TO ARTICLE 15 (INDEMNIFICATION), IN NO EVENT WILL EITHER PARTY BE LIABLE FOR ANY INCIDENTAL, SPECIAL, OR CONSEQUENTIAL DAMAGES RESULTING FROM EXERCISE
OF THIS LICENSE OR THE USE OF THE DATA, MATERIAL, MODIFICATIONS, PROPERTY RIGHTS, OR DERIVED PRODUCTS.
			
		 	(b)	  	EXCEPT FOR LICENSEE’S OBLIGATIONS REGARDING CLAIMS OF THIRD PARTIES PURSUANT TO ARTICLE 15 (INDEMNIFICATION) AND EXCEPT AS MAY RESULT FROM A BREACH OF ARTICLE 22 (CONFIDENTIALITY), NEITHER PARTY WILL BE LIABLE FOR ANY LOST
PROFITS, COSTS OF PROCURING SUBSTITUTE GOODS OR SERVICES, LOST BUSINESS, ENHANCED DAMAGES FOR INTELLECTUAL PROPERTY INFRINGEMENT, OR FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, PUNITIVE, OR OTHER SPECIAL DAMAGES SUFFERED BY THE OTHER PARTY OR ITS
AFFILIATES ARISING OUT OF OR RELATED TO THIS AGREEMENT FOR ALL CAUSES OF ACTION OF ANY KIND (INCLUDING TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY AND BREACH OF WARRANTY) EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH
DAMAGES.

  

	14.4	Nothing in this Agreement is or will be construed as: 

  

	 	(a)	a warranty or representation by The Regents as to the validity, enforceability, or scope of any Property Rights; 

  

	 	(b)	a warranty or representation that anything made, used, offered for Sale, imported, or Sold under any license granted in this Agreement is or will be free from infringement of patents of third parties; 

 

	 	(c)	an obligation to bring or prosecute actions or suits against third parties for misappropriation of Data, Material, Modifications or Derived Products; 

 

	 	(d)	conferring by implication, estoppel, or otherwise any express or implied license or rights under any patents, patent applications, data, copyrights or materials of The Regents, other than with respect to the Data or
Material; or 

  

	 	(e)	an obligation to furnish any know-how, technology, or technological information not provided in the Material. 

  
 11 

 ***Text Omitted and Filed Separately with the Securities and Exchange Commission
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 
  

 15. INDEMNIFICATION 

 

	15.1	Licensee will indemnify, hold harmless, and defend The Regents and its officers, employees, and agents; sponsor(s) of the research that led to the Data and Material; and the creators and inventors of any Data and
Material covered by Property Rights and their employers against any and all claims, suits, losses, damage, costs, fees, and expenses to the extent resulting from, or arising out of, any third party claim relating to the exercise of this license.
This indemnification will include, but will not be limited to, any product liability. If The Regents, in its sole discretion, believes that there will be a conflict of interest with counsel chosen by Licensee, then The Regents may retain counsel of
its choice to represent it, and Licensee will pay all expenses for such representation. 

  

	15.2	Licensee assumes all liability for damages that may arise from its use, storage or disposition of the Material or Modifications. The Regents shall not be liable to Licensee for any loss, claim or demand made by
Licensee, or made against Licensee by any other party, due to or arising from the use, storage or disposition of the Material or Modifications by Licensee. Licensee shall be solely responsible for any use of the Material or Modifications at
Licensee’s facilities or otherwise by Licensee employees, agents, contractors, or other representatives. Licensee shall indemnify, defend, and hold The Regents and all The Regents’ directors, officers, employees, agents, contractors and
other representatives (collectively the “Indemnitees”) harmless from any claim, litigation, liability, inspection, investigation, administrative proceeding, or other action initiated or threatened by a private party, a government agency,
or any other person or entity (collectively “Claims”) arising from receipt, storage, use, or disposition of Materials or Modifications by or on behalf of Licensee pursuant to this Agreement or otherwise, and regardless of the basis or
cause of such Claim. Each Party shall promptly inform the other of any such Claim of which the Party becomes aware, and each shall communicate with the other’s designated counsel regarding the management of such Claim. Licensee shall keep The
Regents informed of, and consult with The Regents in connection with the selection of counsel to defend the any Claim and the progress of such litigation or settlement. Licensee shall not have any right to settle any Claim without the specific prior
written approval from a designated legal representative of The Regents, Licensee acknowledges that any such settlement proposal submitted to The Regents for approval shall contain a full release of liability for The Regents. 

 

	15.3	Licensee, at its sole cost and expense, will insure its activities in connection with any work performed hereunder and will obtain, keep in force, and maintain the following insurance: 

 

	 	(a)	Commercial Form General Liability Insurance (contractual liability included; Commercial Form General Liability Insurance will also include clinical trials insurance coverage when applicable, at the levels below) with
limits as follows: 

  

					
	 Each Occurrence
	  	 	$[...***...]	  
	 Products/Completed Operations Aggregate
	  	 	$[...***...]	  
	 Personal and Advertising Injury
	  	 	$[...***...]	  
	 General Aggregate
	  	 	$[...***...]	  

  
 12 

 ***Text Omitted and Filed Separately with the Securities and Exchange Commission
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 
  

 If the above insurance is written on a claims-made form, it will continue for three
(3) years following termination or expiration of this Agreement. The insurance will have a retroactive date of placement prior to or coinciding with the Effective Date of this Agreement; and 

 

	 	(b)	Worker’s Compensation as legally required in the jurisdiction in which Licensee is doing business. 

  

	15.4	The coverage and limits referred to in Subparagraph 15.3(a) and 15.3(b) above will not in any way limit the liability of Licensee under this Article 15. Upon the execution of this Agreement, Licensee will furnish The
Regents with certificates of insurance evidencing compliance with all requirements, and Licensee will promptly notify The Regents of any material modification of the insurance coverages. Such certificates will: 

 

	 	(a)	provide for thirty (30) days’ (ten (10) days for non-payment of premium) advance written notice to The Regents of any cancellation of insurance coverages; 

 

	 	(b)	indicate that The Regents has been endorsed as an additional insured under the coverage described above in Paragraph 15.3; and 

  

	 	(c)	include a provision that the coverage will be primary and will not participate with, nor will be excess over, any valid and collectable insurance or program of self-insurance maintained by The Regents.

  

	15.5	The Regents will promptly notify Licensee in writing of any claim or suit brought against The Regents for which The Regents intends to invoke the provisions of this Article 15. Licensee will keep The Regents informed of
its defense of any claims pursuant to this Article 15. 

 16. COMPLIANCE WITH LAWS/EXPORT CONTROLS 

 

	16.1	Licensee will comply with all applicable international, national, state, regional, and local laws and regulations in performing its obligations hereunder and in Licensee’s use, manufacture, offer for Sale, Sale, or
import of the Derived Products. Licensee will observe all applicable United States and foreign laws and regulations governing the transfer of Derived Products and related technical data to foreign countries, including, without limitation, the
International Traffic in Arms Regulations (ITAR) and the Export Administration Regulations. 

  

	16.2	 Licensee understands that The Regents is subject to United States laws and regulations (including the Arms Export Control Act, as amended, and the
Export Administration Act of 1979), controlling the export of technical data, computer software, laboratory prototypes and other commodities, and The Regents’ obligations to Licensee under this Agreement are contingent on and subject to
compliance with such laws and regulations. 

  
 13 

 ***Text Omitted and Filed Separately with the Securities and Exchange Commission
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 
  

 
The transfer of certain technical data and/or commodities may require a license from the cognizant agency of the United States Government and/or written assurances by Licensee that Licensee will
not export such technical data and/or commodities to certain foreign countries without prior approval of such agency. The Regents neither represents that such a license will not be required nor that, if required, it will be issued. 

17. GOVERNMENT APPROVAL OR REGISTRATION 
  

	17.1	If this Agreement or any associated transaction is required by the law of any nation to be either approved or registered with any governmental agency, Licensee will assume all legal obligations to do so. Licensee will
notify The Regents if it becomes aware that this Agreement is subject to a United States or foreign government reporting or approval requirement. Licensee will make all necessary filings and pay all costs including fees, penalties, and all other
out-of-pocket costs associated with such reporting or approval process. 

 18. ASSIGNMENT 

 

	18.1	This Agreement is binding upon and will inure to the benefit of The Regents, its successors and assigns. This Agreement is personal to Licensee and assignable by Licensee only with the written consent of The Regents,
provided that Licensee may, on written notice to The Regents, assign this Agreement, including, without limitation, all obligations owed to The Regents hereunder, to an acquiror of all or substantially all of Licensee’s stock or assets to which
this Agreement relates. 

 19. NOTICES 
  

	19.1	All notices under this Agreement will be deemed to have been fully given and effective when done in writing and delivered in person, or mailed by registered or certified U.S. mail, or deposited with a carrier service
requiring signature by recipient, and addressed as follows; 

  

			
	To The Regents:	  	 UC Davis InnovationAccess
 1850 Research Park
Drive, Suite 100
 Davis, CA 95618-6134
 Attn.: Executive
Director,
 File No. [...***...]

		
	To Licensee:	  	 Sage Therapeutics, Inc.
 215 First Street

Cambridge, Massachusetts 02142
 Attention: Chief Business
Officer

 Either Party may change its address upon written notice to the other Party. 

  
 14 

 ***Text Omitted and Filed Separately with the Securities and Exchange Commission
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 
  

 20. PAYMENTS 
  

	20.1	Payments to The Regents that are not for the Material Fee will be made by check or bank wire transfer, to the following address: 

  

			
	Checks:	  	 The Regents of the University of California

Innovation Alliances and Services
 1111 Franklin Street, 5th
Floor
 Oakland, CA 94607-5200
 Attention: Chief Financial
Officer
 Referencing: [...***...]

	
	Bank wire (Licensee is responsible for all wire transfer fees):

 [...***...] 

Payments to The Regents for the Material Fee shall be made by check or bank wire transfer to the address below. Licensee is responsible for all
wire transfer fees. Payments shall be made payable to “The Regents of the University of California”. 
 [...***...] 

In addition to the above, recipient shall return the chain of custody document signed by recipient to UC DAVIS at the above address within one
(1) business day of receipt of shipment of the MATERIAL. 
  

	20.2	If monies owed to The Regents under this Agreement are not received by The Regents when due, Licensee will pay to The Regents interest charges at a rate of [...***...] percent ([...***...]%) per annum. Such
interest will be calculated from the date payment was due until actually received by The Regents. Such accrual of interest will be in addition to, and not in lieu of, enforcement of any other rights of The Regents related to such late payment.
Acceptance of any late payment will not constitute a waiver under Article 21 (Waiver) of this Agreement. 

 21. WAIVER

  

	21.1	The failure of either Party to assert a right hereunder or to insist upon compliance with any term or condition of this Agreement will not constitute a waiver of that right or excuse a similar subsequent failure to
perform any such term or condition by the other Party. None of the terms and conditions of this Agreement can be waived except by the written consent of the Party waiving compliance. 

22. CONFIDENTIALITY 
  

	22.1	Subject to Paragraphs 22.2 and 22.3 below, each Party will hold the other Party’s business and technical information, and other proprietary information, including the negotiated terms of this Agreement
(“Confidential Information”), in confidence and against disclosure to third parties with at least the same degree of care as it exercises to protect its own information and data of a similar nature. This obligation will expire ten
(10) years after the termination or expiration of this Agreement. 

  
 15 

 ***Text Omitted and Filed Separately with the Securities and Exchange Commission
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 
  

	22.2	Nothing contained herein will in any way restrict or impair the right of Licensee or The Regents to use, disclose or otherwise deal with any information or data which: 

 

	 	(a)	at the time of disclosure to a receiving Party is available to the public or thereafter becomes available to the public by publication or otherwise through no act of the receiving Party; 

 

	 	(b)	the receiving Party can show by written record was in its possession prior to the time of disclosure to it hereunder and was not acquired directly or indirectly from the disclosing Party; 

 

	 	(c)	is independently made available to the receiving Party without restrictions by a third party; 

  

	 	(d)	is independently developed by employees of the receiving Party who did not have access to the information disclosed by the disclosing Party; or 

 

	 	(e)	is subject to disclosure under the California Public Records Act or other requirements of law. 

  

	22.3	The Regents will be free to release to its inventors, senior administrators employed by The Regents, and individual Regents, the terms and conditions of this Agreement upon their request. Licensee will be free to
disclose the terms and conditions of this Agreement in connection with the filing of INDs and to bona fide potential or actual advisors, consultants, investors, acquirers, lenders, investment bankers or other potential financial partners in
connection with Licensee’s proposed financing or business combination activities. If any such release described in this Paragraph 22.3 is made, the applicable Party will inform the recipient(s) of the confidentiality obligations set forth above
and will request that they do not disclose such terms and conditions to others. 

  

	22.4	Licensee and The Regents agree to destroy or return to the disclosing Party Confidential Information received from the other in its possession within fifteen (15) days following the effective date of termination of
this Agreement. However, each Party may retain one copy of Confidential Information of the other solely for archival purposes in non-working files for the sole purpose of verifying the ownership of the Confidential Information, provided such
Confidential Information will be subject to the confidentiality provisions set forth in this Article 22. Licensee and The Regents agree to provide each other, within thirty (30) days following termination of this Agreement, with a written
notice that Confidential Information has been returned or destroyed. 

 23. PUBLICATION OF RESEARCH USE RESULTS AND
ACKNOWLEDGEMENT 
  

	23.1	 Licensee may publish or present Research Use Results, provided Licensee provides The Regents with a copy of any proposed manuscript, abstract, poster
session or presentation at least thirty (30) days prior to such publication or presentation. The Regents shall review such publication or presentation for Confidential Information or patentable material and may request a delay of the proposed
publication or presentation for up to an additional thirty (30) days to allow for the removal of Confidential Information or the 

  
 16 

 ***Text Omitted and Filed Separately with the Securities and Exchange Commission
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 
  

	 	
filing of patent application(s). Notwithstanding the foregoing, the Parties agree that no publication or presentation shall contain Confidential Information with respect to which it has
confidentiality obligations pursuant to Article 22 (Confidentiality) of this Agreement without prior written consent of the Party whose Confidential Information is to be disclosed. Unless The Regents directs otherwise, any publication or
presentation including press releases reporting the research carried out with the Material, Modifications or Data shall contain proper referencing in academic journal format or appropriate format, acknowledging UC Davis and The Regents as the source
of the Material and/or Data. 

  

	23.2	Notwithstanding the above, if either Party determines that a clinical investigation utilizing the Material must or should be listed with the National Library of Medicine (ClinicalTrials.gov) or other databases to
satisfy the requirements of the FDA Amendments Act of 2007 (“FDAAA”) or guidelines promulgated by the International Committee of Medical Journal Editors (“ICMJE”), the Parties shall meet and/or confer to create and upload one or
more mutually agreeable listing(s). 

 24. DISCLOSURE, INVENTORSHIP, AND INTELLECTUAL PROPERTY RIGHTS 

 

	24.1	Licensee shall promptly notify The Regents of any potentially patentable discoveries or inventions made through the use of the Material, whether or not made within the specified limits of the approved Research Use.
Licensee shall promptly supply The Regents with a copy of the invention disclosure. 

  

	24.2	Inventorship shall be determined according to United States patent law. 

  

	24.3	Collaborative efforts of The Regents and Licensee may create inventorship rights under United States patent law as well as under the law of any applicable jurisdiction in which a Party or both Parties may elect to file
patent application(s). Each Party shall own its undivided interest in joint inventions. The Parties shall cooperate in discussing and securing patent rights to protect potentially patentable inventions. 

25. FORCE MAJEURE 
  

	25.1	Except for Licensee’s obligation to make any payments to The Regents hereunder, and subject to Paragraph 25.2, below, the Parties will be excused from any performance required hereunder if such performance is
rendered impossible or infeasible due to any catastrophe or other major event beyond their reasonable control, including, without limitation, war, riot, and insurrection; laws, proclamations, edicts, ordinances, or regulations; strikes, lockouts, or
other serious labor disputes; and floods, fires, explosions, or other natural disasters. When such events have abated, the Parties’ respective obligations hereunder will resume. 

 

	25.2	Either Party to this Agreement will have the right to terminate this Agreement upon thirty (30) days’ prior written notice if either Party is unable to fulfill its obligations under this Agreement due to any
of the causes specified in Paragraph 25.1 above for a period of one (1) year. 

  
 17 

 ***Text Omitted and Filed Separately with the Securities and Exchange Commission
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 
  

 26. SEVERABILITY 

 

	26.1	The provisions of this Agreement are severable, and in the event that any provision of this Agreement is determined to be invalid or unenforceable under any controlling body of law, such invalidity or enforceability
will not in any way affect the validity or enforceability of the remaining provisions hereof. 

 27. APPLICABLE LAW; VENUE;
ATTORNEYS’ FEES 
  

	27.1	THIS AGREEMENT WILL BE CONSTRUED, INTERPRETED, AND APPLIED IN ACCORDANCE WITH THE LAWS OF THE STATE OF CALIFORNIA, excluding any choice of law rules that would direct the application of the laws of another jurisdiction.
Any legal action brought by the Parties relating to this Agreement will be conducted in San Francisco, California. The prevailing Party in any legal action under this Agreement will be entitled to recover its reasonable attorneys’ fees in
addition to its costs and necessary disbursements. 

 28. SCOPE OF AGREEMENT 

 

	28.1	This Agreement incorporates the entire agreement between the Parties with respect to the subject matter hereof and supersedes all previous communications, representations or understandings, whether oral or written,
between the Parties relating to the subject matter hereof. The MTA specified in the Recitals above, effective July 9, 2013, is hereby superseded. For the avoidance of doubt, the IND Data Transfer Agreement has expired as of October 1,
2013; however, the surviving provisions of the IND Data Transfer Agreement will continue to exist. 

  

	28.2	This Agreement may be altered or modified only by written amendment duly executed by the Parties. 

 In witness
whereof, the Parties have executed this Agreement in duplicate originals by their duly authorized officers or representatives. 
  

									
	SAGE THERAPEUTICS, INC.	 		 	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
					
	By:	 	/s/ Kiran Reddy	 		 	By:	 	/s/ David R. McGee
	Name:	 	Kiran Reddy	 		 	Name:	 	David R. McGee
	Title:	 	Chief Business Officer	 		 	Title:	 	Executive Director, UC Davis InnovationAccess
	Date:	 	October 21, 2013	 		 	Date:	 	October 23, 2013

  
 18 

 ***Text Omitted and Filed Separately with the Securities and Exchange Commission
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 
  

 First Amendment to the Non-Exclusive License Agreement 

between The Regents of the University of California and Sage Therapeutics, Inc. 

for Allopregnanolone in the Treatment of Status Epilepticus 

and Post-Partum Depression 

UC Agreement Control No. 2014-01-0261 

(File No. [...***...]) 

This first amendment to the Non-Exclusive License Agreement (UC Agreement Control No. 2014-01-0261; File No. [...***...]) for
“Allopregnanolone in the Treatment of Status Epilepticus and Post-Partum Depression” (“First Amendment”) is effective on the 14th day of May, 2014 (“First Amendment Effective Date”) between The Regents of the University
of California (“The Regents”), a California corporation, having its statewide administrative offices at 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200, acting through UC Davis InnovationAccess, with an address at 1850
Research Park Drive, Suite 100, Davis, California 95618-6153, and Sage Therapeutics, Inc. (“Licensee”), a Delaware corporation, having a principal place of business at 215 First Street, Cambridge, Massachusetts 02142. The Regents and
Licensee will be referred to herein, on occasion, individually as “Party” or collectively as “Parties”. 
 Recitals

 Whereas, a Non-Exclusive License Agreement for “Allopregnanolone in the Treatment of Status Epilepticus and Post-Partum
Depression” was entered into between The Regents and Licensee on October 23, 2013, having UC Agreement Control Number 2014-01-0261; File No. [...***...] (“Agreement”); and 

Whereas, the Parties desire to amend the Agreement by adding treatment of essential tremor to Derived Products, Licensed Field of Use and
milestone fees provisions of the Agreement. 

  

 ***Text Omitted and Filed Separately with the Securities and Exchange Commission
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 
  

 The Parties agree as follows: 

1. The title of the Agreement is deleted in its entirety and replaced with the following: 

Non-Exclusive License Agreement between The Regents of the University of California and Sage Therapeutics, Inc. for Allopregnanolone in the
Treatment of Essential Tremor, Status Epilepticus, and Post-Partum Depression 
 2. Paragraph 1.4 of Article 1 (Definitions) of the
Agreement is deleted in its entirety and replaced with the following: 
  

	 	1.4	“Derived Product” means a product containing Allopregnanolone produced by or on behalf of Licensee for Sale or Sold as a drug for essential tremor, status epilepticus, and/or post-partum depression.

 3. Paragraph 1.6 of Article 1 (Definitions) of the Agreement is deleted in its entirety and replaced with the following:

  

	 	1.6	“Licensed Field of Use” means the (a) use of Data for Reference Use as defined below and (b) use of Material or Modifications for Research Use as defined below. 

(i) “Reference Use” means use of Data by the Licensee, and by affiliates, contractors, consultants, agents and/or vendors on behalf
of Licensee, for the sole purpose of reference or incorporation to the extent that such reference or incorporation identifies, labels it as an excerpt from Data and acknowledges UC Davis as the source of the Data in Licensee’s IND
application(s) with the FDA for use of Allopregnanolone for the treatment of essential tremor, status epilepticus, and/or post-partum depression. [...***...]. 

(ii) “Research Use” means use of Material or Modifications to develop a clinically relevant pharmaceutical formulation and use of
such pharmaceutical formulation for FDA-approved human clinical trials for treatment of essential tremor, status epilepticus, and/or post-partum depression. Research Use includes transfer of Material by Licensee to a third party who uses such
Material to create a Modification on behalf of Licensee. 
 4. Paragraph 5.7 of Article 5 (Royalties and Milestones) of the Agreement is
deleted in its entirety and replaced with the following: 
  

	 	5.7      (a)	Within [...***...] days after the [...***...], whichever occurs first, Licensee will pay to The Regents a one-time, non-refundable and non-creditable milestone fee of [...***...] dollars
($[...***...]). 

  
 2 

 ***Text Omitted and Filed Separately with the Securities and Exchange Commission
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 
  

	 	           (b)	Within [...***...] days after the [...***...], whichever occurs second and for which a milestone fee was not paid under Paragraph 5.7(a), Licensee will pay to The Regents a one-time, non-refundable and
non-creditable milestone fee of [...***...] dollars ($[...***...]). 

  

	 	           (c)	Within [...***...] days after the [...***...], whichever occurs third and for which a milestone fee was not paid under Paragraph 5.7(a) or Paragraph 5.7(b), Licensee will pay to The Regents a one-time,
nonrefundable and non-creditable milestone fee of [...***...] dollars ($[...***...]). 

  

	 	           (d)	For clarity, the milestone fees in clauses (a), (b), and (c) above shall each be payable only once, [...***...]. 

This First Amendment does not in any way affect the unamended provisions of the Agreement. 

In witness whereof, the Parties have executed this First Amendment in duplicate originals by their duly authorized officers or representatives. 

 

									
	SAGE THERAPEUTICS, INC.	 		 	 THE REGENTS OF THE UNIVERSITY

OF CALIFORNIA

					
	By:	 	 /s/ Kimi Iguchi
	 		 	By:	 	 /s/ David R. McGee

	Name:	 	 Kimi Iguchi
	 		 	Name:	 	 David R. McGee

	Title:	 	 CFO
	 		 	Title:	 	 Executive Director, UC Davis InnovationAccess

	Date:	 	 5/12/14
	 		 	Date:	 	 5/14/14

  
 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00233-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00233-of-00352.parquet"}]]